

CITATION REPORT

List of articles citing

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcin

DOI: 10.1056/nejmoa0810699

New England Journal of Medicine, 2009, 361, 947-57.

Source: <https://exaly.com/paper-pdf/46821674/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2160	New drug therapies, dedicated specialists and desperately-ill patients-but who will fly the flag for service developments in lung cancer as NHS budgets come under pressure?. 2011 , 5, 209		
2159	Shape evolution of lead telluride and selenide nanostructures under different hydrothermal synthesis conditions. 2006 , 6, 1050-3		41
2158	Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. 2009 , 119, 3000-10		268
2157	Lung cancer: current diagnosis and treatment. 2009 , 106, 809-18; quiz 819-20		46
2156	EGFR genomic alterations in cancer: prognostic and predictive values. 2009 , E3, 879		3
2155	Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. 2009 , 27, 6052-69		88
2154	Biological prognostic and predictive factors in lung cancer. 2009 , 77 Suppl 1, 90-6		24
2153	Chemotherapy of advanced non-small cell lung cancer. 2010 , 42, 157-163		17
2152	Systematically linking drug susceptibility to cancer genome aberrations. 2009 , 8, 3652-6		3
2151	Treatment of lung cancer. <i>New England Journal of Medicine</i> , 2009 , 361, 2485; author reply 2486-7	59.2	14
2150	Personalized medicine and inhibition of EGFR signaling in lung cancer. <i>New England Journal of Medicine</i> , 2009 , 361, 1018-20	59.2	146
2149	The role of EGFR inhibition in the treatment of non-small cell lung cancer. 2009 , 14, 1116-30		44
2148	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. 2009 , 15, 7502-7509		115
2147	Parallel paths to predictive biomarkers in oncology: Uncoupling of emergent biomarker development and phase III trial execution. 2009 , 1, 10ps11		8
2146	Highlights From: The 13th World Conference on Lung Cancer San Francisco, CA July 31âAugust 4, 2009. 2009 , 10, 317-321		
2145	Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. 2009 , 10, 392-4		16
2144	Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. 2009 , 10, 395-404		2

2143	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 2009 , 625, 6-22	18
2142	Lung cancer outcomes in women. 2009 , 36, 532-41	13
2141	Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. 2009 , 36, 572-80	41
2140	Biomarker für die individualisierte Behandlung solider Tumoren. 2009 , 2, 134-140	
2139	Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. 2009 , 462, 1070-4	766
2138	Gefitinib efficacy in adenocarcinoma. 2009 , 6, 617-617	
2137	Lessons from the lung for targeted anticancer drugs. 2009 , 8, 758-9	2
2136	The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC. 2009 , 28 Suppl 1, S1-3	5
2135	Epidermal growth factor receptor inhibitors: current status and future directions. 2009 , 33, 245-94	9
2134	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. 2009 , 27, 6251-66	619
2133	Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer. 2009 , 23, 392-397	2
2132	Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. 2009 , 69, 2303-28	39
2131	Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors. 2009 , 11 Suppl 3, S24	2
2130	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. 2009 , 10, 1102-10	21
2129	Analyse des facteurs prédictifs de réponse au traitement par cetuximab dans le CBNPC avancé ou métastatique en traitement de 1re ligne. 2009 , 65, H13-H14	
2128	2009 : l'année de la maintenance en première ligne ?. 2009 , 65, S75-S79	
2127	[Individualized treatment of metastatic non small cell lung carcinoma: a promising beginning]. 2009 , 26, 1039-40	
2126	Le cetuximab en 1re ligne de traitement dans les CBNPC. 2009 , 65, H19-H21	

2125	Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. 2010 , 21, 151-68	9
2124	Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?. 2010 , 21, 799-804	9
2123	Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. 2010 , 5, 1105-6	30
2122	Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. 2010 , 7, 121-124	2
2121	Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. 2010 , 5, 1551-8	105
2120	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. 2010 , 5, 1706-13	237
2119	Gefitinib or Carboplatin+Paclitaxel in Pulmonary Adenocarcinoma. 2010 , 2010, 149-151	1
2118	The genomics of lung adenocarcinoma: opportunities for targeted therapies. 2010 , 1, 1200-10	64
2117	Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. 2010 , 11, 851-64	40
2116	Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. 2010 , 5, 1048-53	68
2115	Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. 2010 , 5, 1011-7	61
2114	Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. 2010 , 5, 1977-85	47
2113	Inaktive Kinasekonformationen stabilisieren. 2010 , 58, 118-121	2
2112	Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer. 2010 , 5, 1524-8	59
2111	Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. 2010 , 22, 112-20	36
2110	Molecular Diagnostics Testing for Lung Adenocarcinoma. 2010 , 15, 103-110	1
2109	Is it prime time for personalized medicine in cancer treatment?. 2010 , 7, 387-397	1
2108	Current world literature. 2010 , 22, 155-61	

2107	Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis. 2010 , 16, 315-20	10
2106	Initial evaluation of the nonsmall cell lung cancer patient: diagnosis and staging. 2010 , 16, 307-14	23
2105	Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity. 2010 , 16, 635-42	15
2104	Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. 2010 , 5, 1477-80	25
2103	Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. 2010 , 5, 436-41	172
2102	Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. 2010 , 5, 620-30	188
2101	Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. 2010 , 5, 1001-10	92
2100	Non-small cell lung cancer. 2010 , 8, 740-801	457
2099	Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. 2010 , 5, 1616-22	106
2098	Recent development of molecular-targeted drugs in lung cancer. 2010 , 49, 1923-34	6
2097	Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. 2010 , 5, 1623-9	79
2096	Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. 2010 , 5, 1949-52	29
2095	Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. 2010 , 5, 1404-9	42
2094	[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer]. 2010 , 54, 137-43	
2093	Molecular origins of lung cancer: prospects for personalized prevention and therapy. 2010 , 5, S207-13	4
2092	Epidermal growth factor receptor pathway. 2010 , 5, S470-1	1
2091	Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: deal or no deal?. 2010 , 5, 1495-7	2
2090	Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. 2010 , 5, 1855-8	32

2089	Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. 2010 , 5, 1424-9	26
2088	A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. 2010 , 5, 1664-7	100
2087	Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. 2010 , 5, 562-71	33
2086	A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. 2010 , 5, 69-74	35
2085	Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. 2010 , 5, 411-4	144
2084	Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. 2010 , 5, 719-20	34
2083	Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. 2010 , 5, 442-7	184
2082	Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. 2010 , 5, 1609-15	29
2081	Maintenance therapy in advanced non-small cell lung cancer. 2010 , 5, 723-34	15
2080	A comparison study of clinicopathologic characteristics of Southern California Asian American Non-small Cell Lung Cancer (NSCLC) patients by smoking status. 2010 , 5, 158-68	10
2079	Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?. 2010 , 8, 822-32	31
2078	Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients. 2010 , 5, 1042-7	9
2077	Best of the month: a roundup of articles published in recent months. 2010 , 5, 1305-7	2
2076	Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung. 2010 , 3, 87-93	
2075	Systemische Therapie des nichtkleinzelligen Bronchialkarzinoms. 2010 , 3, 113-117	
2074	Lungenkrebs: vom Gen zur Therapie. 2010 , 3, 81-86	
2073	Discovering neuroprotection in Parkinson's disease, or getting to haphazard. 2010 , 77, 700-6	2
2072	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. 2010 , 28, 4769-77	214

2071	[Molecular diagnostics in lung carcinoma for therapy stratification]. 2010 , 31, 22-8	3
2070	[Lung cancer: genetic screening before starting therapy]. 2010 , 51 Suppl 1, 303-5	
2069	[Lung cancer from the perspective of internal medicine and surgery]. 2010 , 50, 662-8	3
2068	Die Prim�rtherapie des nichtkleinzelligen Lungenkarzinoms. 2010 , 24, 97-104	
2067	Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. 2010 , 457, 483-95	39
2066	Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. 2010 , 136, 527-35	11
2065	Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. 2010 , 136, 1937-44	25
2064	Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements. 2010 , 128, 567-75	10
2063	Soins sp�tifiques, soins de support � l'effort combat !. 2010 , 12, 555-557	
2062	Efficacy of cetuximab combination with chemotherapy in non-small cell lung cancer first-line setting: the summary based on publications. 2010 , 9, 137-141	3
2061	Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer: a report of 6 cases. 2010 , 9, 502-506	2
2060	VEGF and EGFR inhibition: opening a new door to cancer treatment. 2010 , 42, 24-28	1
2059	Onko Update 2010. 2010 , 16, 417-419	
2058	Lungenkarzinom. 2010 , 16, 615-628	3
2057	Swiss trials in thoracic oncology. 2010 , 3, 37-40	
2056	Changing paradigms in clinical trials. 2010 , 3, 1-2	0
2055	EMT in NSCLC and malignant pleural mesothelioma. 2010 , 3, 180-184	
2054	Impact of biomarkers on non-small cell lung cancer treatment. 2010 , 5, 5-17	14

2053	EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. 2010 , 5, 245-55	50
2052	Personalized medicine in lung adenocarcinoma: no longer a hope or a passing fashion, but a new reality. 2010 , 5, 229-30	
2051	Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours. 2010 , 4, 11-21	33
2050	Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. 2010 , 12, 75-80	33
2049	SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. 2010 , 12, 735-41	11
2048	Chemotherapy Foundation Symposium XXVIII Innovative Cancer Therapy For Tomorrow Abstracts 2010. 2010 , 11, 1-104	6
2047	Oral cancer chemotherapy: the critical interplay between patient education and patient safety. 2010 , 12, 247-52	64
2046	Molecular testing in lung cancer: the time is now. 2010 , 12, 335-48	18
2045	Treatment of advanced non-small cell lung cancer with extracorporeal high frequency thermotherapy combined with Chinese medicine. 2010 , 16, 406-10	14
2044	âTargeted therapiesâIn der Behandlung solider Tumoren. 2010 , 3, 48-51	
2043	Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy. 2010 , 124, 177-86	11
2042	Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. 2010 , 29, 37-48	75
2041	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. 2010 , 29, 49-60	164
2040	Int�t� des biomarqueurs en cancfologie. 2010 , 21, 12-13	
2039	Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. 2010 , 140, e69-71	43
2038	Aortic dissection and rupture in adolescents after tetralogy of Fallot repair. 2010 , 140, e71-3	43
2037	A target or a demi-target. 2010 , 11, 147-8	2
2036	The emerging role of biomarkers in advanced non-small-cell lung cancer. 2010 , 11, 149-59	18

2035	Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component. 2010 , 11, 160-8	6
2034	Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer. 2010 , 11, 257-63	7
2033	Extended-duration therapy in advanced non-small-cell lung cancer: promise and pitfalls. 2010 , 11, 383-90	1
2032	Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. 2010 , 10, 285	49
2031	Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature. 2010 , 10, 49	13
2030	Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. 2010 , 10, 570	10
2029	Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient. 2010 , 3, 195	8
2028	Circulating tumour-derived predictive biomarkers in oncology. 2010 , 15, 98-101	24
2027	Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. 2010 , 80, 613-23	69
2026	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. 2010 , 17, 77-88	816
2025	Kinases as targets in the treatment of solid tumors. 2010 , 22, 984-1002	71
2024	Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. 2010 , 584, 2699-706	110
2023	Individualized medicine 2010. 2010 , 14, 2257-63	1
2022	Response to 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis'?(Paz-Ares et al., J Cell Mol Med. 2010; 14: 51-69). 2010 , 14, 2693-4	
2021	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. 2010 , 2, 146-58	333
2020	Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer. 2010 , 116, 670-5	84
2019	Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. 2010 , 116, 4309-17	17
2018	Physicians optimistic about advances in lung cancer and melanoma treatment. 2010 , 116, 2287-8	

2017	Detection of EGFR and KRAS mutations in fine-needle aspirates stored on Whatman FTA cards: is this the tool for biobanking cytological samples in the molecular era?. 2010 , 118, 450-6	42
2016	Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance. 2010 , 11, 2557-66	34
2015	Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. 2010 , 102, 852-5	50
2014	Lung cancer proteomics, clinical and technological considerations. 2010 , 73, 1851-63	33
2013	Is there a standard of care for the radical management of non-small cell lung cancer involving the apical chest wall (Pancoast tumours)?. 2010 , 22, 334-46	14
2012	Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland. 2010 , 22, 550-3	
2011	Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. 2010 , 101, 2033-8	17
2010	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. 2010 , 29, 2346-56	185
2009	Translating cancer research into targeted therapeutics. 2010 , 467, 543-9	269
2008	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. 2010 , 10, 760-74	802
2007	Integrating molecular diagnostics into anticancer drug discovery. 2010 , 9, 523-35	45
2006	Personalized medicine in oncology: the future is now. 2010 , 9, 363-6	219
2005	Evolving R&D for emerging markets. 2010 , 9, 417-20	19
2004	Advances in understanding cancer genomes through second-generation sequencing. 2010 , 11, 685-96	890
2003	Predictive biomarkers in the management of EGFR mutant lung cancer. 2010 , 1210, 45-52	8
2002	From genomic landscapes to personalized cancer management-is there a roadmap?. 2010 , 1210, 34-44	14
2001	Lung cancer: progress in diagnosis, staging and therapy. 2010 , 15, 44-50	73
2000	The current status of targeted therapy for non-small cell lung cancer. 2010 , 40, 611-8	17

1999	Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. 2010 , 17, 13-23	26
1998	Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). 2010 , 4, 81-98	34
1997	Management of patients with advanced non-small cell lung cancer: role of gefitinib. 2010 , 4, 83-90	1
1996	Refining the treatment of advanced nonsmall cell lung cancer. 2010 , 1, 9-22	1
1995	Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer. 2010 , 1, 37-51	
1994	Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. 2010 , 1, 10	1
1993	Molecular Diagnosis in Lung Cancer. 2010 , 9, 9	2
1992	Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. 2010 , 2010, 709678	16
1991	Genomic aberrations in lung adenocarcinoma in never smokers. 2010 , 5, e15145	54
1990	PNA-Mediated PCR Clamping for the Detection of EGFR Mutations in Non-Small Cell Lung Cancer. 2010 , 69, 271	9
1989	Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. 2010 , 4, 237-43	7
1988	The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. 2010 , 4, 289-98	25
1987	Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. 2010 , 2, 143-56	19
1986	Biomarkers are here to stay for clinical research and standard care. 2010 , 5, 1113-5	5
1985	EGFR-mutated lung cancer: a paradigm of molecular oncology. 2010 , 1, 497-514	143
1984	Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives. 2010 , 1, 77-84	20
1983	Prevention of Lung Cancer: Future Perspective with Natural Compounds. 2010 , 69, 1	5
1982	Radiation Recall Pneumonitis Induced by Gefitinib in a Patient with Lung Adenocarcinoma and EGFR Mutation. 2010 , 50, 937-941	1

1981	Possibility of using mRNA expression levels for nucleic acid-metabolizing enzymes within prostate cancer cells as indices for prognostic factors. 2010 , 1, 1049-1053		1
1980	The future role of personalized medicine in the treatment of glioblastoma multiforme. 2010 , 3, 111-27		12
1979	Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. 2010 , 16, 3349-55		91
1978	Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma. 2010 , 28, 903-5		22
1977	Lung cancer: multidisciplinary approach for management: cell and molecular biology assembly contribution to the celebration of 20 years of the ERS. 2010 , 35, 717-20		8
1976	The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations. 2010 , 2, 301-7		26
1975	Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. 2010 , 7, 71-2		8
1974	Consequences of targeted treatments for second-line therapy. 2010 , 21 Suppl 7, vii234-40		4
1973	Targeted therapies for non-small cell lung cancer: an evolving landscape. 2010 , 9, 1931-44		65
1972	Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. <i>New England Journal of Medicine</i> , 2010 , 363, 1727-33	59.2	622
1971	Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?. 2010 , 16, 5956-62		32
1970	[Molecular characteristics of lung cancer]. 2010 , 97, 1323-35		3
1969	Reply to A. Ocana et al. 2010 , 28, e422-e423		
1968	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. 2010 , 28, 4616-20		277
1967	Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. 2010 , 16, 3163-70		98
1966	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. 2010 , 28, 3076-83		343
1965	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. 2010 , 16, 5873-82		168
1964	clAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer. 2010 , 16, 5200-10		58

1963	Refocusing the war on cancer: the critical role of personalized treatment. 2010 , 2, 28cm13	26
1962	Clinical implications of the cancer genome. 2010 , 28, 5219-28	156
1961	The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. 2010 , 6, 1827-32	19
1960	A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. 2010 , 16, 1561-71	364
1959	Circulating tumour cells: their utility in cancer management and predicting outcomes. 2010 , 2, 351-65	174
1958	Equipoise lost: ethics, costs, and the regulation of cancer clinical research. 2010 , 28, 2925-35	75
1957	A therapeutic target for smoking-associated lung cancer. 2010 , 2, 62ps56	18
1956	Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. 2010 , 70, 5024-33	91
1955	Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. 2010 , 70, 8025-35	55
1954	A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. 2010 , 16, 3078-87	77
1953	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. 2010 , 16, 5581-90	284
1952	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. 2010 , 16, 5489-98	175
1951	The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. 2010 , 19, 186-96	28
1950	Update on nonsmall cell lung cancer. 2010 , 19, 173-85	14
1949	Progress in cancer chemotherapy with special stress on molecular-targeted therapy. 2010 , 40, 855-62	15
1948	What is the role of maintenance therapy in the treatment of non-small cell lung cancer?. 2010 , 2, 229-35	3
1947	Living with imperfection. 2010 , 28, 191-2	30
1946	Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. 2010 , 2, 62ra93	646

1945	Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials. 2010 , 5, 153-60	6
1944	Epidermal growth factor receptor tyrosine kinase inhibitors for elderly patients with advanced non-small cell lung cancer. 2010 , 348174	1
1943	Treating advanced non-small cell lung cancer in the elderly. 2010 , 2, 251-60	26
1942	Advances in target therapy for lung cancer. 2010 , 40, 101-6	58
1941	Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. 2010 , 15, 1102-12	56
1940	If histology matters. 2010 , 28, 1810-2	10
1939	A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. 2010 , 16, 4647-53	89
1938	How to integrate current knowledge in selecting patients for first line in NSCLC?. 2010 , 21 Suppl 7, vii230-3	5
1937	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010 , 21 Suppl 5, v116-9	236
1936	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 1693-703	59.2 3577
1935	Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer. 2010 , 11, 1683-93	7
1934	Novel biomarkers of metastatic cancer. 2010 , 10, 581-90	12
1933	A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. 2010 , 10, 955-65	11
1932	Targeted therapies: Molecular selection for 'smart' study design in lung cancer. 2010 , 7, 621-2	3
1931	EGF receptor in lung cancer: a successful story of targeted therapy. 2010 , 10, 1577-87	12
1930	Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer. 2010 , 103, 1325-30	11
1929	Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. 2010 , 10, 1589-99	5
1928	Novel strategies for treating relapsed/refractory urothelial carcinoma. 2010 , 10, 1917-32	13

1927	Prognostic and predictive factors in resected non-small-cell lung cancer. 2010 , 4, 373-81	7
1926	Personalized medicine for non-small-cell lung cancer. 2010 , 10, 1601-11	10
1925	New biomarkers for lung cancer. 2010 , 4, 201-24	9
1924	Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. 2010 , 14, 1073-90	120
1923	Re-overcoming barriers in translating biomarkers to clinical practice. 2010 , 4, 103-12	2
1922	Targeted therapy at the end of life for patients with lung cancer. 2010 , 13, 945-8	15
1921	Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. 2010 , 56, 623-32	82
1920	Redefining disease. 2010 , 10, 584-94	11
1919	Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. 2010 , 16, 4616-24	68
1918	Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. 2010 , 70, 868-74	165
1917	The tissue is the issue: personalized medicine for non-small cell lung cancer. 2010 , 16, 4909-11	58
1916	The evolving role of histology in the management of advanced non-small-cell lung cancer. 2010 , 28, 5311-20	220
1915	Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. 2010 , 16, 1324-30	85
1914	Targeted therapies in small cell lung cancer: a review. 2010 , 2, 25-37	36
1913	Phase II clinical trials in oncology: are we hitting the target?. 2010 , 10, 427-38	7
1912	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. 2010 , 70, 9827-36	164
1911	Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. 2010 , 28, 5116-23	58
1910	Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. 2010 , 70, 8715-25	128

1909	[Lung cancer: an update in 2010]. 2010 , 97, 161-9	3
1908	Biological response modifiers: current use and future prospects in cancer therapy. 2010 , 47, 443-51	16
1907	Gefitinib. 2010 , 6, 249-54	8
1906	Delivering on the promise of personalized healthcare. 2010 , 7, 327-337	9
1905	Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer. 2010 , 10, 933-41	10
1904	Dramatic responses to gefitinib when used as front line therapy in two cases of metastatic lung adenocarcinoma with poor performance status. 2010 , 6, 362-4	2
1903	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. 2010 , 12, 1193-9	201
1902	A growing family: adding mutated Ergb4 as a novel cancer target. 2010 , 9, 1487-503	30
1901	Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. 2010 , 78, 249-58	32
1900	Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. 2010 , 5, 1933-8	46
1899	Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. 2010 , 79, 423-9	38
1898	Histology matters: individualizing treatment in non-small cell lung cancer. 2010 , 15, 3-5	22
1897	The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. 2010 , 21, 2023-2028	60
1896	Can a decisional algorithm be used in first-line treatment of advanced nonsmall cell lung cancer?. 2010 , 22, 77-8	
1895	Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer. 2010 , 7, 360-2	5
1894	Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy. 2010 , 7, 426-8	6
1893	Individualisierte Therapie für Patienten mit fortgeschrittenen Lungenkarzinomen. 2010 , 31, 79-87	
1892	[Prevention, diagnosis, therapy, and follow-up of lung cancer]. 2010 , 64 Suppl 2, e1-164	85

1891	[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?]. 2010 , 64, 727-35	2
1890	[Predictive medicine - clinical genetics 2010]. 2010 , 135, 1334-8	0
1889	Clinical year in review I: interstitial lung disease, pulmonary vascular disease and venous thromboembolism, diagnostic imaging, and lung cancer. 2010 , 7, 297-304	
1888	Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. 2010 , 6, 741-67	18
1887	Chemotherapy for advanced non-small-cell lung cancer patients with poor performance. 2010 , 3, 623-6	
1886	EGFR Mutation Testing in Non-Small Cell Lung Cancer. 2010 , 6, 310-321	2
1885	Genetics of gestational trophoblastic neoplasia: an update for the clinician. 2010 , 6, 1915-23	11
1884	Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. 2010 , 10, 549-57	1
1883	Predictive genomic biomarkers. 2012 , 355, 173-88	1
1882	Past, present and future of targeted therapy in solid tumors. 2010 , 10, 433-61	26
1881	Novel agents in the management of lung cancer. 2010 , 17, 4291-325	16
1880	Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. 2010 , 4, 499-508	5
1879	Improving women's health: advances, failures and cancer genome prospects. 2010 , 6, 769-72	
1878	Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies. 2010 , 10, 799-812	23
1877	Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. 2010 , 28, 4609-15	130
1876	Update in lung cancer and mesothelioma 2009. 2010 , 181, 773-81	11
1875	Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. 2010 , 11, 2363-89	18
1874	[Clinical case No. 3 proposed by the V. Westeel (CHU Besançon) team]. 2010 , 66, H13-8	

1873 La stadification (« staging ») endoscopique. **2010**, 2, 206-211

1872 Oncologie thoracique. **2010**, 2, 167-177

1

1871 [Pretreatment molecular biology analysis on small size biopsies]. **2010**, 30, 67-72

2

1870 La stratgie de maintenance en premièe ligne de traitement dans les cancers bronchiques non ^ petites cellules avancs. **2010**, 2, 286-297

1869 Ciblage thfapeutique du cancer pulmonaire non ^ petites cellules (CPNPC) : (encore) des promesses?. **2010**, 2, 524-526

1868 [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)]. **2010**, 66, 367-74

1867 Les nouveauts en matièe de traitements biologiques des CBNPC. **2010**, 2, 275-281

0

1866 Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. **2010**, 11, 1149-67

107

1865 Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy. **2010**, 7, 618-9

12

1864 Hematology: Is thalidomide combination a new option for myeloma?. **2010**, 7, 425-6

1863 Targeted therapies for non-small cell lung cancer. **2010**, 67, 257-74

130

1862 Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. **2010**, 68, 319-31

50

1861 Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. **2010**, 69, 265-71

10

1860 Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report. **2010**, 68, 498-500

11

1859 Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. **2010**, 70, 320-8

41

1858 Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). **2010**, 70, 301-7

34

1857 Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer. **2010**, 69, 259-64

16

1856 Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. **2010**, 70, 223-5

20

1855	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?. 2010 , 7, 401-14	205
1854	Updates in non-small cell lung cancer--insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. 2010 , 3, 18	12
1853	Management of patients with advanced non-small cell lung cancer: current and emerging options. 2010 , 70, 167-79	17
1852	Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib. 2010 , 11, 57-60	6
1851	The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. 2010 , 11, 82-90	26
1850	Second-line treatment for non-small-cell lung cancer: one size does not fit all. 2010 , 11, 320-7	10
1849	Pharmacogenetics: Making cancer treatment safer and more effective. 2010 ,	1
1848	Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. 2010 , 16, 1307-14	155
1847	The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer. 2010 , 41, 951-9	9
1846	Molecular networks in respiratory epithelium carcinomas. 2010 , 295, 1-6	
1845	Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. 2010 , 13, 67-78	124
1844	Parameters for individualizing systemic therapy in non-small cell lung cancer. 2010 , 13, 196-204	12
1843	Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. 2010 , 46, 869-79	42
1842	Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. 2010 , 46, 2166-77	62
1841	The biology and treatment of EML4-ALK non-small cell lung cancer. 2010 , 46, 1773-80	417
1840	Nasopharyngeal carcinoma: the next challenges. 2010 , 46, 1967-78	181
1839	Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib. 2010 , 46, 2045-51	13
1838	Bauhinia variegata var. variegata trypsin inhibitor: from isolation to potential medicinal applications. 2010 , 396, 806-11	24

1837	Biomarkers in lung oncology. 2010 , 23, 508-14		10
1836	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. 2010 , 28, 4953-60		296
1835	The molecular pathology of cancer. 2010 , 7, 251-65		182
1834	Gefitinib for the treatment of non-small-cell lung cancer. 2010 , 11, 1343-57		19
1833	Recent developments in the treatment of non-small cell lung cancer. 2010 , 7, 105-107		
1832	The controversy surrounding adjuvant therapy for resectable NSCLC is over. 2010 , 7, 107-108		
1831	ALK inhibitors: a major step in the right direction. 2010 , 7, 444		
1830	PARP inhibition in BRCA-mutated breast and ovarian cancers. 2010 , 376, 211-3		38
1829	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. 2010 , 36 Suppl 3, S21-9		97
1828	Surgical oncology: why biopsying metastatic breast cancer should be routine. 2010 , 7, 72-4		15
1827	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. <i>New England Journal of Medicine</i> , 2010 , 362, 2380-8	59.2	4177
1826	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. 2010 , 28, 918-27		237
1825	Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. 2010 , 28, 744-52		424
1824	Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer. 2010 , 109, 338-44		5
1823	Population-based differences in treatment outcome following anticancer drug therapies. 2010 , 11, 75-84		110
1822	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. 2010 , 11, 121-8		3140
1821	Targeting the target: a step forward for the treatment of non-small-cell lung cancer. 2010 , 11, 104-5		6
1820	Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?. 2010 , 11, 500-1		2

1819	Molecularly targeted therapy: when to stop and when to continue?. 2010 , 11, 709-11	5
1818	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. 2010 , 11, 619-26	364
1817	One more fallen star--ZODIAC and its implications. 2010 , 11, 604-5	1
1816	Bevacizumab in lung cancer: hurdles in clinical development. 2010 , 11, 703-4	3
1815	Clinical Pharmacology: Current Topics and Case Studies. 2010 ,	
1814	EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. <i>New England Journal of Medicine</i> , 2010 , 363, 1734-9	59.2 940
1813	First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer. 2010 , 29, 126	11
1812	Clinical protein science and bioanalytical mass spectrometry with an emphasis on lung cancer. 2010 , 110, 3278-98	30
1811	Advances in chemotherapy in advanced non-small-cell lung cancer. 2010 , 11, 2997-3007	26
1810	Generalized or personalized treatment for stage IIIA-N2 non-small-cell lung cancer?. 2010 , 11, 1605-9	4
1809	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. 2010 , 28, 3965-72	291
1808	New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. 2010 , 19, 1503-14	8
1807	Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. 2010 , 102, 298-306	58
1806	EGFR mutations, gene amplification, and protein expression and KRAS mutations in primary and metastatic tumors of nonsmall cell lung cancers and their clinical implications: a meta-analysis. 2011 , 29, 626-34	15
1805	Suppression of epidermal growth factor receptor (EGFR) expression by small hairpin RNA inhibits the growth of human nonsmall cell lung cancers bearing wild-type and mutant EGFR. 2011 , 29, 701-8	3
1804	Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222. 2011 , 29, 266-71	3
1803	Expert conference on cancer pain assessment and classification--the need for international consensus: working proposals on international standards. 2011 , 1, 281-7	47
1802	Advances in cancer therapeutics and patient access to new drugs. 2011 , 29, 213-24	12

1801	Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. 2011 , 15, 347-52	55
1800	Motesanib and advanced NSCLC: experiences and expectations. 2011 , 20, 859-69	9
1799	Integrating biomarkers in clinical trials. 2011 , 11, 171-82	104
1798	American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. 2011 , 29, 2121-7	414
1797	Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. <i>N Engl J Med</i> 2010;363(18):1693-703. 2011 , 15, 351-3	29
1796	Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. 2011 , 29, 1556-63	658
1795	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. 2011 , 29, 3307-15	343
1794	A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. 2011 , 17, 1553-60	89
1793	Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). 2011 , 29, 2866-74	1102
1792	A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. 2011 , 13, 74-84	155
1791	Translational proteomics: what can you do for true patients?. 2011 , 10, 101-4	3
1790	Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR. 2011 , 8, 571-3	12
1789	(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. 2011 , 52, 1684-1689	74
1788	Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. 2011 , 108, 7535-40	445
1787	Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. 2011 , 8, 2069-79	40
1786	The BATTLE trial: personalizing therapy for lung cancer. 2011 , 1, 44-53	660
1785	9122 POSTER Efficacy of Gefitinib in Patients With Epidermal Growth Factor Receptor Mutation Positive Advanced Non-Small-Cell Lung Cancer -a Metaanalysis of Randomized Controlled Trials. 2011 , 47, S630	
1784	[Management of patients with resistance to EGFR-TKI]. 2011 , 67 Suppl 1, S30-5	

1783	[A simple view on lung cancer biology: The EGFR pathway]. 2011 , 28, 565-77		9
1782	Diagnostic workup of lung cancer. 2011 , 20, 667-79		3
1781	[Sampling and search for the EGFR mutation: what's taking, when and how to test?]. 2011 , 67 Suppl 1, S9-14		1
1780	L'impact des thérapies ciblées chez le patient atteint de cancer au stade palliatif. 2011 , 10, 51-63		
1779	9121 POSTER A Multi-center, Open, Randomized, Phase II Study to Investigate the Sequential Administration of Docetaxel and Intermittent Erlotinib Versus Erlotinib as a Second-line Therapy for Advanced Non-small Cell Lung Cancer (NSCLC). 2011 , 47, S630		
1778	Actualités en oncologie thoracique. 2011 , 3, 515-518		
1777	[What choice of first-line treatment?]. 2011 , 67 Suppl 1, S20-3		
1776	Quelle est la meilleure séquence thérapeutique chez les patients ayant un CBNPC avec mutation activatrice de l'EGFR ?. 2011 , 3, 376-379		
1775	A decade of advances in treatment for advanced non-small cell lung cancer. 2011 , 32, 839-51		50
1774	Oncologie. 2011 , 3, 40-48		
1773	Traitement d'induction et de maintenance des CBNPC au stade métastatique. 2011 , 3, 365-371		
1772	Treatment of non-small-cell lung cancer with erlotinib or gefitinib. <i>New England Journal of Medicine</i> , 2011 , 364, 947-55	59.2	309
1771	Pemetrexed in advanced non-small cell lung cancer. 2011 , 10, 311-7		13
1770	Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. 2011 , 11, 1223-31		25
1769	Targeting the human EGFR family in esophagogastric cancer. 2011 , 8, 492-503		120
1768	Cancer: beyond speciation. 2011 , 112, 283-350		52
1767	Genomics and the continuum of cancer care. <i>New England Journal of Medicine</i> , 2011 , 364, 340-50	59.2	247
1766	Pathology of lung cancer. 2011 , 32, 669-92		346

1765	Lung cancer in 2010: One size does not fit all. 2011 , 8, 68-70	44
1764	Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. 2011 , 8, 485-504	39
1763	Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. 2011 , 50, 582-8	11
1762	Recomendaciones para la determinaci3n de las mutaciones del gen EGFR en el carcinoma de pulm3n no microc3nico. 2011 , 44, 17-31	2
1761	Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. 2011 , 72, 205-12	62
1760	Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. 2011 , 72, 199-204	43
1759	Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. 2011 , 71, 3-10	314
1758	Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. 2011 , 73, 96-102	106
1757	Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience. 2011 , 73, 189-94	45
1756	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. 2011 , 71, 249-57	92
1755	Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. 2011 , 72, 3-8	35
1754	Lung cancer in never smokers: change of a mindset in the molecular era. 2011 , 72, 9-15	65
1753	Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib. 2011 , 73, 211-6	12
1752	Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. 2011 , 74, 85-8	18
1751	Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer. 2011 , 74, 98-102	24
1750	The search for improved systemic therapy of non-small cell lung cancer--what are today's options?. 2011 , 72, 265-70	17
1749	Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. 2011 , 74, 293-9	20
1748	Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. 2011 , 73, 1-10	21

1747	High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. 2011 , 74, 384-91	10
1746	Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. 2011 , 74, 457-61	68
1745	Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. 2011 , 74, 469-73	53
1744	Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the Lung cancer maNagement) study. 2011 , 74, 462-8	11
1743	Fifth Educational Symposium of the Spanish Lung Cancer Group: report on the Molecular Biology Workshop. 2011 , 74, 535-43	1
1742	EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer. 2011 , 73, 249-55	14
1741	Tissue sampling in lung cancer: a review in light of the MERIT experience. 2011 , 74, 1-6	32
1740	Predictive markers in the adjuvant therapy of non-small cell lung cancer. 2011 , 74, 355-63	21
1739	Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure. 2011 , 74, 349-51	20
1738	What is the true prevalence of EGFR mutations in India?. 2011 , 74, 549	
1737	Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. 2011 , 12, 113-24	81
1736	Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. 2011 , 5, 471-85	129
1735	Personalized medicine in lung cancer: what we need to know. 2011 , 8, 661-8	118
1734	Tumours. 2011 , 531-705	
1733	A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer. 2011 , 34, 175-86	6
1732	Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. 2011 , 50, 371-403	80
1731	Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. 2011 , 71, 79-88	6
1730	Targeted therapies for gastric cancer: current status. 2011 , 71, 1367-84	31

1729	Role of genotyping in non-small cell lung cancer treatment: current status. 2011 , 71, 2231-46	17
1728	Case records of the Massachusetts General Hospital. Case 21-2011. A 31-year-old man with ALK-positive adenocarcinoma of the lung. <i>New England Journal of Medicine</i> , 2011 , 365, 158-67	59.2 8
1727	Targeting the Wnt Pathway in Cancer. 2011 ,	5
1726	Encyclopedia of Cancer. 2011 , 2100-2104	4
1725	Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. 2011 , 10, 495-506	200
1724	Encyclopedia of Cancer. 2011 , 2005-2025	
1723	The potential for crizotinib in non-small cell lung cancer: a perspective review. 2011 , 3, 279-91	62
1722	The BATTLE to personalize lung cancer prevention through reverse migration. 2011 , 4, 962-72	40
1721	Résultats des stratégies ciblées des cancers bronchiques non ^petites cellules en 2011. 2011 , 3, 423-427	
1720	Oncologie thoracique. 2011 , 3, 158-165	
1719	Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. 2011 , 56, 275-84	67
1718	Advances in Personalized Cancer Management. 2011 ,	
1717	[Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences]. 2011 , 67 Suppl 1, S15-9	
1716	[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments]. 2011 , 67 Suppl 1, S36-40	1
1715	[What is the best sequence of treatment for patients with EGFR mutations?]. 2011 , 67 Suppl 1, S24-9	1
1714	Principles of Anticancer Drug Development. 2011 ,	
1713	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. 2011 , 1, 608-25	108
1712	Survival and death signals can predict tumor response to therapy after oncogene inactivation. 2011 , 3, 103ra99	34

1711 Oncologie thoracique. **2011**,

1710 Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. **2011**, 3, 90ra59 383

1709 BIBW 2992 in non-small cell lung cancer. **2011**, 20, 415-22 7

1708 9123 POSTER Final Results of a Phase II Study of Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Non-small Cell Lung Cancer and Gefitinib for Elderly Patients With Lung Adenocarcinoma. **2011**, 47, S630

1707 Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer. **2011**, 56, 30-8 24

1706 Importance of molecular features of non-small cell lung cancer for choice of treatment. **2011**, 178, 1940-8 36

1705 Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. **2011**, 179, 580-9 20

1704 The evolving war on cancer. **2011**, 145, 19-24 174

1703 Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer. **2011**, 10, 245-57 17

1702 Use of molecular markers for predicting therapy response in cancer patients. **2011**, 37, 151-9 82

1701 Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?. **2011**, 37, 533-42 28

1700 Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. **2011**, 37, 456-64 55

1699 [Targeted therapies and radiation therapy in non-small cell lung cancer]. **2011**, 15, 527-35 4

1698 Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. **2011**, 14, 177-90 42

1697 CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)_n polymorphism. **2011**, 47, 1962-70 27

1696 Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer. **2011**, 47, 2415-21 10

1695 A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). **2011**, 47, 2331-40 93

1694 Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. **2011**, 47, 2603-6 86

1693	Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. 2011 , 38, 903-10	27
1692	EGFR and KRAS mutations in metastatic lung adenocarcinomas. 2011 , 42, 1447-53	47
1691	[Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues]. 2011 , 40, 379-88	0
1690	[Non-small cell lung carcinoma: Perspectives for the twenty-first century?]. 2011 , 40, 368-70	0
1689	[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]. 2011 , 40, 371-8	5
1688	[Adverse effects of new biological therapies for non-small-cell bronchial cancer]. 2011 , 40, 415-9	3
1687	Pharmacogenomic biomarkers: new tools in current and future drug therapy. 2011 , 32, 72-81	78
1686	2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment--first-line therapy. 2011 , 47 Suppl 3, S248-57	5
1685	Second-line treatment options in advanced non-small cell lung cancer. 2011 , 47 Suppl 3, S258-71	1
1684	Systemic treatment of non-small-cell lung cancer. 2011 , 47 Suppl 3, S375-7	6
1683	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. 2011 , 12, 735-42	3028
1682	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. 2011 , 12, 795-805	175
1681	Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?. 2011 , 12, 710-1	21
1680	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. 2011 , 12, 1004-12	732
1679	Imaging of lung cancer in the era of molecular medicine. 2011 , 18, 424-36	33
1678	Prognostic proof and possible therapeutic mechanisms of herbal medicine in patients with metastatic lung and colon cancer. 2011 , 10, NP1-NP11	8
1677	The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. 2011 , 11, 673-82	34
1676	Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. 2011 , 73, 361-5	62

1675 Cancer broncho-pulmonaire chez le non-fumeur. **2011**, 163-194

1674 Unraveling the genetics of cancer: genome sequencing and beyond. **2011**, 12, 407-30

73

1673 Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. **2011**, 1, 78-89

389

1672 Epidermal growth factor receptor mutation-guided treatment for lung cancers: Where are we now?. **2011**, 2, 1-6

4

1671 Therapeutic advances in non-small cell lung cancer: Highlights from the annual clinical cancer conferences. **2011**, 8, 5-16

1670 Emerging therapeutic options for advanced non-small cell lung cancer. **2011**, 8, 13-16

1669 Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. **2011**, 29, 1701-8

149

1668 First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. **2011**, 22, 559-566

61

1667 Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. **2011**, 71, 350-5

31

1666 A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. **2011**, 71, 65-9

27

1665 First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer â Review. **2011**, 3, 116-120

4

1664 Personalized therapy for non-small cell lung cancer: hype or clinical reality?. **2011**, 23, 30-5

2

1663 Sex and gender differences in non-small cell lung cancer. **2011**, 23, 137-45

42

1662 Personalized therapy for non-small cell lung cancer: which drug for which patient?. **2011**, 23, 281-90

9

1661 [The relevance of head-to-head trials to patient-centred clinical research]. **2011**, 105, 639-45

1

1660 Non-small-cell lung cancer. **2011**, 378, 1727-40

517

1659 Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. **2011**, 18, 126-38

90

1658 Tyrosine kinase inhibitors: Multi-targeted or single-targeted?. **2011**, 2, 80-93

131

1657	Systemic Therapy for Lung Cancer for the Radiation Oncologist. 2011 , 247-266	
1656	From Clinical Trials to Clinical Practice: Predictors of Response to Erlotinib in Advanced Non-Small Cell Lung Cancer Patients Pretreated with Chemotherapy. 2011 , 97, 160-165	9
1655	Pathology of Lung Cancer. 2011 , 53-62	
1654	Comparison of Therapeutic Efficacy of Gefitinib and Erlotinib in Patients with Squamous Cell Lung Cancer. 2011 , 71, 15	4
1653	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. 2011 , 4, 1-9	2
1652	Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy. 2011 , 10, 1	2
1651	Effectiveness of maintenance treatments for nonsmall cell lung cancer. 2011 , 2, 29-39	
1650	Histologic Features of ALK-Expressing Adenocarcinomas of the Lung. 2011 , 10, 32	3
1649	Comparative Analysis of Peptide Nucleic Acid (PNA)-Mediated Real-Time PCR Clamping and DNA Direct Sequencing for EGFR Mutation Detection. 2011 , 70, 21	9
1648	Advances in the prevention and treatment of lung cancer. 2011 , 41, 142-9	5
1647	Afatinib treatment in advanced non-small cell lung cancer. 2011 , 2, 47-57	3
1646	Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. 2011 , 17, 469-80	89
1645	Targeted cancer therapies. 2011 , 30, 1-4	39
1644	EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy. 2011 , 2, 383-387	4
1643	EGFR genomic alterations in cancer: prognostic and predictive values. 2011 , 3, 879-87	23
1642	MET and phosphorylated MET as potential biomarkers in lung cancer. 2011 , 30, 341-54	19
1641	Successful erlotinib treatment for a patient with gefitinib-related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib. 2011 , 2011, 812972	4
1640	Cell death signaling and anticancer therapy. 2011 , 1, 5	36

1639	Non-small cell lung cancer: the challenges of the next decade. 2011 , 1, 29	5
1638	Radiation Sensitizers. 2011 , 213-222	1
1637	Benchmarking of mutation diagnostics in clinical lung cancer specimens. 2011 , 6, e19601	95
1636	Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. 2011 , 6, e23303	38
1635	Molecular Biology and Genetics of Lung Cancer. 2011 , 3-15	2
1634	Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010). 2011 , 6, 227-32	1
1633	Maintenance therapy in advanced non-small cell lung cancer: current status and future implications. 2011 , 6, 174-82	30
1632	Current world literature. 2011 , 23, 120-30	
1631	The new staging system for lung cancer: imaging and clinical implications. 2011 , 26, 119-31	10
1630	Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. 2011 , 22, 1010-9	16
1629	Reply to M.C. Garassino et al. 2011 , 29, 3837-3837	
1628	Company Profile: N-of-One: realizing personalized medicine. 2011 , 8, 311-315	
1627	A phase II study of gefitinib in patients with metastatic melanoma. 2011 , 21, 357-63	30
1626	First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?. 2011 , 23, 131-2	0
1625	Malignant neurocristic hamartoma: a tumor distinct from conventional melanoma and malignant blue nevus. 2011 , 35, 1570-7	20
1624	Tumor genotyping for breast cancer: at the front door. 2011 , 8, 383-385	
1623	Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations. 2011 , 90, 159-167	26
1622	Novel therapies for non-small cell lung cancer. 2011 , 26, 175-85	10

1621	Factors driving the choice of the best second-line treatment of advanced NSCLC. 2011 , 6, 44-51	14
1620	Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?. 2011 , 90, 168-170	4
1619	Novel therapeutic targets in non-small cell lung cancer. 2011 , 6, 1601-12	110
1618	Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. 2011 , 11, 732-9	6
1617	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. 2011 , 6, 707-15	140
1616	Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study. 2011 , 6, 1092-7	20
1615	New discoveries in lung cancer biology: paving the road of personalized medicine. 2011 , 8, 1-4	
1614	Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. 2011 , 23, 88-92	34
1613	What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. 2011 , 43, 103-15	46
1612	Gefitinib or Chemotherapy for Non-small-Cell Lung Cancer with Mutated EGFR. 2011 , 2011, 93-95	2
1611	Breathe contributes to the ERS Action Plan for Thoracic Oncology. 2011 , 7, 219-220	
1610	A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. 2011 , 6, 1639-48	67
1609	Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. 2011 , 6, 1849-56	103
1608	Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. 2011 , 6, 569-75	102
1607	Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study. 2011 , 6, 148-55	22
1606	Anticancer treatment for advanced non-small cell lung cancer. 2011 , 8, 124-133	2
1605	Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. 2011 , 6, 21-7	133
1604	Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. 2011 , 6, 1663-9	35

1603	Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. 2011 , 6, 627-30	57
1602	Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. 2011 , 6, 103-8	42
1601	KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. 2011 , 25, 1021-9	15
1600	An approach to personalized medicine: the BATTLE trial. 2011 , 1, 699-705	
1599	Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. 2011 , 6, 1763-73	57
1598	Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project-part 1). 2011 , 6, 1006-15	43
1597	First case of A859T epidermal growth factor receptor mutation responding to erlotinib. 2011 , 6, 639-40	3
1596	How I do it--optimal methodology for multidirectional analysis of endobronchial ultrasound-guided transbronchial needle aspiration samples. 2011 , 6, 203-6	92
1595	EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. 2011 , 121, 4712-21	177
1594	Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). 2011 , 6, 1872-80	106
1593	Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. 2011 , 6, 2112-9	23
1592	Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. 2011 , 2, 685-693	28
1591	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. 2011 , 6, 1474-80	131
1590	Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. 2011 , 6, 905-12	53
1589	A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. 2011 , 6, 1379-91	79
1588	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. 2011 , 6, 774-80	185
1587	Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. 2011 , 6, 489-93	74
1586	Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. 2011 , 6, 28-31	107

1585	A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. 2011 , 6, 1110-6	24
1584	Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. 2011 , 6, 1128-31	67
1583	A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer. 2011 , 6, 1569-77	29
1582	EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. 2011 , 6, 947-50	37
1581	[Recent progress for chemotherapy in advanced non-small cell lung cancer]. 2011 , 100, 763-71	
1580	[The cutting-edge of medicine; Ethnic and gender differences in lung cancer]. 2011 , 100, 3064-71	
1579	Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors. 2011 , 2, 1059-1064	1
1578	Investigation of the flexibility of bronchoscopes. 2011 , 16, 420-4	1
1577	Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. 2011 , 6, 1413-7	46
1576	Maintaining aim at a moving target. 2011 , 6, 417-22	8
1575	The diverse diversity. 2011 , 6, 842-3	1
1574	Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. 2011 , 6, 139-47	53
1573	Annual review of advances in non-small cell lung cancer research: a report for the year 2010. 2011 , 6, 1443-50	5
1572	Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib. 2011 , 6, 1946-9	10
1571	NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. 2011 , 9 Suppl 5, S1-32; quiz S33	195
1570	Novel Targeted Agents and Radiopharmaceuticals in Lung Cancer. 2011 , 773-790	
1569	Targeted therapy: an evolving world of lung cancer. 2011 , 16, 13-21	14
1568	Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. 2011 , 102, 1032-7	99

1567	Epidermal growth factor receptor as a therapeutic target in veterinary oncology. 2011 , 9, 81-94	13
1566	Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort. 2011 , 20, 848-50	21
1565	Ex vivo demonstration of a synergistic effect of Adapalene and benzoyl peroxide on inflammatory acne lesions. 2011 , 20, 850-3	27
1564	Harnessing synthetic lethal interactions in anticancer drug discovery. 2011 , 10, 351-64	204
1563	State-of-the-art gene-based therapies: the road ahead. 2011 , 12, 316-28	515
1562	Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. 2011 , 30, 1744-52	35
1561	Interstitial lung disease induced by gefitinib and toll-like receptor ligands is mediated by Fra-1. 2011 , 30, 3821-32	19
1560	Targeting IGF-1R: throwing out the baby with the bathwater?. 2011 , 104, 1-3	25
1559	Charting a course for genomic medicine from base pairs to bedside. 2011 , 470, 204-13	677
1558	Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. 2011 , 7 Suppl 2, 34-40	7
1557	Bevacizumab in the treatment of non-small cell lung cancer: focus on East Asia. 2011 , 7 Suppl 2, 1-3	
1556	Principles of cytotoxic chemotherapy. 2011 , 39, 711-716	11
1555	Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. 2011 , 141, 476-80	35
1554	Classification of lung cancer. 2011 , 46, 178-86	32
1553	Personalized treatment of lung cancer. 2011 , 38, 274-83	33
1552	Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. 2011 , 38, 173-85	49
1551	Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. 2011 , 11, 90	14
1550	A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. 2011 , 30, 111	58

1549	Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. 2011 , 61, 31-49	144
1548	Lung cancer: New biological insights and recent therapeutic advances. 2011 , 61, 91-112	329
1547	Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy. 2011 , 12, 56-61	7
1546	Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: is there a role for targeted therapy in these cohorts?. 2011 , 12, 272-9	19
1545	Biomarkers, prediction, and prognosis in non-small-cell lung cancer: a platform for personalized treatment. 2011 , 12, 360-8	22
1544	Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. 2011 , 12, 387-92	39
1543	EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. 2011 , 12, 380-6	93
1542	Integration of EGFR inhibitors and conventional chemotherapy in the treatment of non-small-cell lung cancer. 2011 , 12, 350-9	14
1541	Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms. 2011 , 12, 261-71	26
1540	Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective. 2011 , 12, 335-40	2
1539	Monoclonal antibodies against EGFR in non-small cell lung cancer. 2011 , 80, 1-9	34
1538	Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). 2012 , 81, 49-57	21
1537	Drug-diagnostic co-development: how to harness the value. 2011 , 16, 902-5	4
1536	Surgical resection of locally advanced pulmonary adenocarcinoma after gefitinib therapy. 2011 , 92, e11-2	16
1535	Activating enhancer-binding protein-2 nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. 2011 , 92, 1044-50	6
1534	Invited commentary. 2011 , 92, 1050	
1533	Resisting targeted therapy: fifty ways to leave your EGFR. 2011 , 19, 437-40	19
1532	NSCLC: novel targeted therapies offer hope for the future. 2011 , 12, 6-9	

1531	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. 2011 , 5, 413-24	21
1530	Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. 2011 , 1, 297-311	40
1529	EGFR mutations and lung cancer. 2011 , 6, 49-69	387
1528	Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?. 2011 , 66, 273-5	6
1527	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. 2011 , 17, 6298-303	330
1526	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. 2011 , 3, 75ra26	2425
1525	Pemetrexed monotherapy and pemetrexed plus platinum combination therapy as non-first-line treatments for advanced non-small cell lung cancer. 2011 , 8, 235-241	
1524	Molecular oncology in lung cancer – between biomarkers and clinical application. Relevance of the Ras/Raf/MEK/ERK pathway. 2011 , 4, 242-247	1
1523	Gender aspects in haematology and oncology: Overview and own observations in lung cancer. 2011 , 4, 209-216	
1522	A histology-based algorithm in the molecular diagnosis of mutations of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC)*. 2011 , 4, 248-253	1
1521	Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. 2011 , 37, 183-93	30
1520	Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs. 2011 , 12, 827-43	13
1519	Primary lung cancer in never smokers. 2011 , 16, 285-6	1
1518	[Histology-based algorithm in the molecular diagnosis of mutations of the Epidermal Growth Factor Receptor (EGFR) in non-small cell lung cancer]. 2011 , 123, 316-21	4
1517	EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. 2011 , 458, 95-8	68
1516	The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. 2011 , 137, 687-94	25
1515	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. 2011 , 137, 1397-408	13
1514	Systemische Therapie des nichtkleinzelligen Lungenkarzinoms. 2011 , 25, 224-230	

1513 Pathophysiologie und Molekular Diagnostik beim nichtkleinzelligen Lungenkarzinom. **2011**, 17, 670-678

1512	Multimodale Therapie des lokal-fortgeschrittenen nichtkleinzelligen Lungenkarzinoms. 2011 , 17, 691-701	0
1511	The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing. 2011 , 16, 335-44	43
1510	Lung cancers unrelated to smoking: characterized by single oncogene addiction?. 2011 , 16, 294-305	22
1509	Pathologie und molekulare Pathologie von Lungentumoren. 2011 , 8, 333-337	
1508	[Complete remission of multiple brain metastases of non-small cell lung cancer induced by gefitinib monotherapy]. 2011 , 187, 826-30	4
1507	[Molecular diagnostics of lung cancer for treatment stratification]. 2011 , 52, 146, 148-50, 152-4	3
1506	[Tyrosine kinase inhibitors in oncology]. 2011 , 52, 595-600	2
1505	Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers. 2011 , 60, 1397-403	2
1504	In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. 2011 , 67, 637-46	48
1503	Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. 2011 , 67, 837-45	49
1502	The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. 2011 , 68, 1485-95	24
1501	Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. 2011 , 68, 1099-109	72
1500	EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. 2011 , 67, 235-43	36
1499	Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib. 2011 , 28, 331-5	3
1498	Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with non-small cell lung cancer: a report of 12 cases. 2011 , 28 Suppl 1, S570-6	2
1497	Targeted therapies in advanced non-small cell lung cancer: success or failure?. 2011 , 4, 23-26	1
1496	Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib. 2011 , 28, 126-33	10

1495	Medicatie bij longcarcinoom. 2011 , 54, 502-505	
1494	Clinical trials in the age of personalized medicine. 2011 , 9, 91-98	3
1493	Targetable "driver" mutations in non small cell lung cancer. 2011 , 2, 178-88	17
1492	Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. 2011 , 6, 171-80	9
1491	Pulmonary toxicities from targeted therapies: a review. 2011 , 6, 235-43	77
1490	Hematologic toxicities of small molecule tyrosine kinase inhibitors. 2011 , 6, 203-15	11
1489	Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCER. 2011 , 23, 112-7	2
1488	How affordable are targeted therapies in non-small cell lung cancer?. 2011 , 12, 1-11	11
1487	The optimal chemotherapy for stage III non-small cell lung cancer patients. 2011 , 13, 272-9	6
1486	The evolving role of targeted therapy in early-stage and locally advanced non-small cell lung cancer. 2011 , 13, 280-9	5
1485	Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. 2011 , 11, 1	174
1484	Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma. 2011 , 11, 172	22
1483	Crossing survival curves: alternatives to the log-rank test. 2011 , 12,	18
1482	Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. 2011 , 4, 5	22
1481	Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. 2011 , 12, 97	13
1480	Genetically informed lung cancer medicine. 2011 , 223, 230-40	53
1479	Cancer biology and genomics: translating discoveries, transforming pathology. 2011 , 223, 99-101	4
1478	Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. 2011 , 224, 270-9	62

1477	Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. 2011 , 225, 83-95	38
1476	Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint. 2011 , 30, 1502-18	8
1475	The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. 2011 , 30, 2409-21	262
1474	Targeting the growth factors and angiogenesis pathways: small molecules in solid tumors. 2011 , 103, 574-86	18
1473	Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. 2011 , 103, 773-81	27
1472	Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apicoxib in combination with erlotinib in advanced nonsmall cell lung cancer. 2011 , 117, 809-18	19
1471	Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. 2011 , 117, 143-51	27
1470	Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. 2011 , 117, 3069-80	15
1469	TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. 2011 , 119, 127-33	61
1468	EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. 2011 , 119, 80-91	95
1467	Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs. 2011 , 129, 1410-6	22
1466	Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial. 2011 , 80, 126-32	34
1465	Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study. 2011 , 12, 100-5	5
1464	First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan. 2011 , 12, 116-24	6
1463	Developments for a growing Japanese patient population: facilitating new technologies for future health care. 2011 , 74, 759-64	12
1462	Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. 2011 , 74, 982-92	94
1461	State-of-the-art MS technology applications in lung disease. 2011 , 3, 2665-77	5
1460	Genomic and Cellular Pathology of Lung Cancer. 2011 , 7, 313-322	1

1459	Analysis of protein biomarkers in human clinical tumor samples: critical aspects to success from tissue acquisition to analysis. 2011 , 5, 227-48		4
1458	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. 2011 , 45, 263-75		
1457	[Personalized, targeted treatment of non-small cell lung cancer]. 2011 , 136, 480-5		2
1456	A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. 2011 , 24, 974-82		31
1455	Vandetanib for the treatment of non-small-cell lung cancer. 2011 , 12, 2271-8		3
1454	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer. 2011 , 12, 922-33		24
1453	EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. 2011 , 183, 743-51		50
1452	Treatment of advanced lung cancer in the elderly. 2011 , 39, 107-15		10
1451	Putting genomics into practice. 2011 , 343, d4953		3
1450	Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer. <i>New England Journal of Medicine</i> , 2011 , 365, 1426-35	59.2	5
1449	Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. 2011 , 32, 22-31		128
1448	Systemische Behandlung nicht kleinzelliger und kleinzelliger Lungenkarzinome – Multimodale und molekulare Therapiekonzepte. 2011 , 40, 566-575		
1447	Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. 2011 , 18, 1613-28		30
1446	EGFR-Mutationsanalyse bei immunhistochemischem Nachweis eines pulmonalen Plattenepithelkarzinoms. 2011 , 32, 349-352		
1445	[Thoracic oncology]. 2011 , 136, 2029-32		
1444	Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy. 2011 , 32, 78-93		8
1443	Bronchioloalveolar carcinoma. 2011 , 32, 52-61		8
1442	[Current treatment concepts of lung cancer]. 2011 , 136, 1901-6		0

1441	EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. 2011 , 64, 884-92	28
1440	Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. 2011 , 17, 1160-8	258
1439	Gefitinib for non-small-cell lung cancer treatment. 2011 , 10, 987-96	11
1438	Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. 2011 , 24, 653-64	693
1437	An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. 2011 , 22, 1805-11	25
1436	Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. 2011 , 10, 336-46	123
1435	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. 2011 , 17, 1169-80	467
1434	The importance of ultrasound in staging and gaining a pathological diagnosis in patients with lung cancer--a two year single centre experience. 2011 , 66, 414-7	20
1433	Targeted therapies for lung cancer: clinical experience and novel agents. 2011 , 17, 512-27	80
1432	EGFR mutant lung cancer. 2012 , 355, 59-81	5
1431	Targeting anaplastic lymphoma kinase in lung cancer. 2011 , 17, 2081-6	230
1430	Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin. 2011 , 29, 3835-7; author reply 3837-9	13
1429	Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?. 2011 , 4, 470-4	12
1428	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. 2011 , 6, 2011-7	176
1427	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. 2011 , 17, 5530-7	282
1426	Lung cancer in never smokers. 2011 , 7, 1195-211	30
1425	Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. 2011 , 3, 113-25	77
1424	Biology-driven phase II trials: what is the optimal model for molecular selection?. 2011 , 29, 1236-8	56

1423	Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. 2011 , 16, 1307-15	21
1422	Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. 2011 , 29, 2066-70	195
1421	Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer. 2011 , 17, 39-45	25
1420	Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. 2011 , 20, 45-52	18
1419	Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. 2011 , 29, 4320-6	91
1418	EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. 2011 , 41, 548-54	7
1417	E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. 2011 , 10, 1218-28	13
1416	Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. 2011 , 6, 466-72	243
1415	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. 2011 , 71, 6051-60	468
1414	Accrual to cancer clinical trials in the era of molecular medicine. 2011 , 3, 75cm9	16
1413	Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung. 2011 , 22, 2471-2475	14
1412	Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. 2011 , 11, 1587-97	12
1411	How close are we to customizing chemotherapy in early non-small cell lung cancer?. 2011 , 3, 185-205	8
1410	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. 2011 , 29, 3316-21	184
1409	Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. 2011 , 17, 1616-22	470
1408	Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. 2011 , 16, 886-95	47
1407	CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. 2011 , 29, e443-5	450
1406	EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology. 2011 , 17, 7796-807	32

1405	The importance of evaluation of DNA amplifiability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues. 2011 , 41, 165-71	17
1404	Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. 2011 , 4, 818-28	43
1403	ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice. 2011 , 7, 202-4	17
1402	Next generation radiologic-pathologic correlation in oncology: Rad-Path 2.0. 2011 , 197, 990-7	23
1401	Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study. 2011 , 52, 1573-9	46
1400	Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. 2011 , 22, 2277-85	66
1399	Thfapeutiques ciblès dans le traitement des tumeurs solides. 2011 , 55-89	1
1398	Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. 2011 , 136, 228-38	33
1397	Gefitinib in non small cell lung cancer. 2011 , 2011, 815269	14
1396	Recent progress and clinical importance on pharmacogenetics in cancer therapy. 2011 , 49, 1621-32	5
1395	Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. 2011 , 16, 319-26	61
1394	MicroRNA gene dosage alterations and drug response in lung cancer. 2011 , 2011, 474632	11
1393	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. 2011 , 17, 2260-9	89
1392	Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancer. 2011 , 5, 131-44	21
1391	Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. 2011 , 39, 1392-401	41
1390	Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations. 2011 , 29, 3435-42	28
1389	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. 2011 , 17, 1131-9	148
1388	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. 2011 , 17, 2521-7	103

1387	Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors. 2011 , 57, 108-14	2
1386	The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients. 2011 , 82, 341-50	7
1385	Is FISH floating or still swimming in the lung cancer ocean?. 2011 , 22, 493-499	4
1384	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. 2011 , 22, 1507-1519	98
1383	Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. 2011 , 17, 6322-8	42
1382	Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. 2011 , 17, 6459-66	53
1381	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. 2011 , 6, 244-85	3178
1380	Combining EGF receptor inhibitors with chemotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. 2011 , 8, 9-14	1
1379	Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402. 2011 , 41, 948-52	12
1378	Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. 2011 , 6, e25164	68
1377	Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. 2011 , 135, 1329-34	77
1376	A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach. 2011 , 23, 67-70	1
1375	Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns. 2011 , 6, 1066-72	36
1374	The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. 2011 , 1, 1119-1126	16
1373	[Molecular diagnosis and therapy in oncology]. 2011 , 34 Suppl 2, 5-9	
1372	Non-small cell lung cancer in never-smokers: a new disease entity?. 2011 , 34, 202-7	2
1371	Long-term survival in a smoking caucasian male patient treated with gefitinib for spinal cord compression secondary to lung cancer. 2011 , 34, 326-8	3
1370	Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach. 2011 , 80, 350-8	9

1369	Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study. 2011 , 6, 156-60	7
1368	Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study. 2011 , 6, 1022-9	35
1367	Integrating biomarkers into clinical trials: methodological issues for a new paradigm in nonsmall cell lung cancer. 2011 , 23, 106-11	9
1366	Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!. 2011 , 23, 245-6	3
1365	A new BATTLE in the evolving war on cancer. 2011 , 1, 14-6	10
1364	The potential benefits of BIM in the further pursuit of biomarker discovery in cancer therapeutics. 2011 , 1, 289-90	4
1363	Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. 2011 , 6, 1895-901	96
1362	Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. 2011 , 29, 2972-7	185
1361	Molecular selection trumps clinical selection. 2011 , 29, 2843-4	15
1360	Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. 2011 , 64, 947-52	57
1359	Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. 2011 , 17, 5179-87	59
1358	ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. 2011 , 17, 7394-401	147
1357	Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene. 2011 , 29, e468-9	17
1356	Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. 2011 , 29, 2543-9	52
1355	Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. 2011 , 17, 1190-9	63
1354	Drug approval challenges in the age of personalized cancer treatment. 2011 , 8, 633-640	4
1353	PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. 2011 , 108, E699-708	180
1352	Generation and evaluation of a monoclonal antibody, designated MADL, as a new specific marker for adenocarcinomas of the lung. 2011 , 105, 673-81	4

1351	PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. 2011 , 105, 1920-6	18
1350	Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. 2011 , 105, 1131-6	9
1349	Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. 2011 , 10, 1720-7	109
1348	Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. 2011 , 105, 1-8	45
1347	Chemotherapy: advanced NSCLC--should we use doublets in elderly patients?. 2011 , 8, 694-6	2
1346	The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients. 2011 , 20, 305-7	5
1345	Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. 2011 , 38, 239-43	48
1344	Biostatistical Considerations in Development of Biomarker-Based Tests to Guide Treatment Decisions. 2011 , 3, 549-560	9
1343	New molecular oncology-changing era: prospects and challenges of cancer genome and integrative systems biology. 2011 , 11, 5-8	2
1342	A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. 2011 , 29, 3567-73	69
1341	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. 2011 , 22, 2616-2624	279
1340	FEATURES. 2011 , 15, 14-29	1
1339	A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. 2011 , 10, 1311-6	307
1338	Models of partnership between the pharmaceutical and diagnostics industries around companion diagnostics for cancer and beyond. 2011 , 5, 91-4	
1337	Personalized management for non-small-cell lung cancer. 2011 , 58-67	
1336	Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer. 2011 , 3, 163-70	12
1335	Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked. 2011 , 20, 545-54	24
1334	Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. 2011 , 17, 5562-72	50

1333	Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. 2011 , 22, 1791-7	32
1332	Genetic testing for lung cancer: reflex versus clinical selection. 2011 , 29, 1943-5	13
1331	Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. 2011 , 2011, 165214	92
1330	Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. 2011 , 17, 3812-21	336
1329	Forty years of translational cancer research. 2011 , 1, 383-90	9
1328	Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. 2011 , 29, e819-22	56
1327	Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients. 2011 , 41, 1366-72	12
1326	New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology. 2011 , 28, 539-55	8
1325	HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. 2011 , 25, 92-103	52
1324	An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC). 2011 , 3, 3506-24	4
1323	Target therapies in lung cancer. 2011 , 2011, 921231	7
1322	Pharmacogenetics and pharmacogenomics: a clinical reality. 2011 , 48, 410-7	15
1321	The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer. 2011 , 3, 2667-78	5
1320	Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations. 2011 , 41, 959-63	12
1319	The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. 2011 , 16, 1498-507	38
1318	Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. 2011 , 10, 127-37	20
1317	Challenges in idiopathic pulmonary fibrosis trials: the point on end-points. 2011 , 20, 195-200	16
1316	The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment. 2012 , 19, S16-23	35

1315	The importance of multidisciplinary team management of patients with non-small-cell lung cancer. 2012 , 19, S7-S15	38
1314	Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. 2012 , 19, S73-85	9
1313	Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions. 2012 , 19, 42-6	5
1312	Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?. 2012 , 8, 224-30	6
1311	Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer. 2012 , 8, 373-8	6
1310	Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. 2012 , 23, 1223-1229	21
1309	Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. 2012 , 23, 1023-9	14
1308	Epidermal growth factor receptor (EGFR) inhibitors and derived treatments. 2012 , 23 Suppl 10, x193-6	12
1307	Mucinous tumours of the ovary. 2012 , 65, 580-4	24
1306	A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. 2012 , 18, 1435-46	135
1305	Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. 2012 , 19, S52-8	96
1304	Molecular diagnostics of lung cancers at the Brigham and Women's Hospital and Dana-Farber Cancer Institute: technology in rapid evolution. 2012 , 136, 1198-200	7
1303	Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer. 2012 , 2012, 419402	2
1302	Going beyond EGFR. 2012 , 23 Suppl 10, x197-203	8
1301	A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada. 2012 , 19, 78-90	8
1300	Personalized medicine and treatment approaches in non-small-cell lung carcinoma. 2012 , 5, 113-23	16
1299	Review of the treatment of non-small cell lung cancer with gefitinib. 2012 , 6, 407-21	20
1298	KRAS wild-type lung cancer: a moving target in an era of genotype migration. 2012 , 30, 3322-4	9

1297	Ancillary testing in lung cancer diagnosis. 2012 , 2012, 249082	13
1296	Personalized targeted therapy for lung cancer. 2012 , 13, 11471-96	45
1295	EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer. 2012 , 19, e67-74	13
1294	First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients. 2012 , 33, 146-54	7
1293	egfr tyrosine kinase inhibitors in lung cancer: make no assumptions. 2012 , 19, 8	1
1292	Non-small-cell lung carcinoma subtyping on cytology without the use of immunohistochemistry - can we meet the challenge?. 2012 , 56, 413-8	3
1291	Neoadjuvant erlotinib and surgical resection of a stage iiiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation. 2012 , 19, e222-6	12
1290	Hope for progress after 40 years of futility? Novel approaches in the treatment of advanced stage III and IV non-small-cell-lung cancer: Stereotactic body radiation therapy, mediastinal lymphadenectomy, and novel systemic therapy. 2012 , 11, 20	4
1289	The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLC from one institution. 2012 , 5, 349-55	10
1288	Supportive care treatments for toxicities of anti-egfr and other targeted agents. 2012 , 19, S59-63	30
1287	Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. 2012 , 23, 1010-6	17
1286	Hurdles in anticancer drug development from a regulatory perspective. 2012 , 9, 236-43	26
1285	Attitudes of patients with cancer about personalized medicine and somatic genetic testing. 2012 , 8, 329-35, 2 p following 335	79
1284	New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. 2012 , 18, 3002-7	28
1283	Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. 2012 , 7, 1471-3	47
1282	MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. 2012 , 13, 255-60	95
1281	Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. 2012 , 7, 355-64	66
1280	Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. 2012 , 18, 220-8	76

1279	Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. 2012 , 39, 366-72	78
1278	Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. 2012 , 7, 1315-26	135
1277	Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors. 2012 , 11, 795-804	67
1276	Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?. 2012 , 30, 1750-4	57
1275	Clinical development of new formulations of cytotoxics in solid tumors. 2012 , 24, 325-31	6
1274	Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. 2012 , 24, 297-304	15
1273	Detection of EGFR mutation in tissue samples of non-small-cell lung cancer by a fluorescence polarization assay. 2012 , 21, 138-42	2
1272	IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma: novel concepts and radiologic implications. 2012 , 27, 340-53	48
1271	Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. 2012 , 72, 100-11	512
1270	Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. 2012 , 30, 3337-44	214
1269	Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012 , 23 Suppl 7, vii56-64	342
1268	Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung. 2012 , 8, 267-74	56
1267	Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. 2012 , 11, 2535-40	39
1266	Using companion and coupled diagnostics within strategy to personalize targeted medicines. 2012 , 9, 751-761	8
1265	Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. 2012 , 8, 57-62	3
1264	Personalized therapy of lung cancer. 2012 , 35 Suppl 1, 14-9	5
1263	The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. 2012 , 65, 1-7	27
1262	Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. 2012 , 23, 670-677	38

1261	Intratumor heterogeneity: seeing the wood for the trees. 2012 , 4, 127ps10	375
1260	Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer. 2012 , 17, 682-93	28
1259	ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. 2012 , 30, 878-9	38
1258	Statistical issues and recommendations for noninferiority trials in oncology: a systematic review. 2012 , 18, 1837-47	43
1257	Differential diagnosis of lung carcinoma with three-dimensional quantitative molecular vibrational imaging. 2012 , 17, 066017	8
1256	KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach. 2012 , 63, 145-64	27
1255	MiR-23a regulates TGF- β -induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. 2012 , 41, 869-75	140
1254	Emerging targeted therapies for lymphoid malignancies. 2012 , 136, 476-82	0
1253	Method to our madness or madness in our methods? Pitfalls in trial methodology. 2012 , 30, 2025-7	3
1252	Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. 2012 , 19, e9-e15	35
1251	Cancer genes in lung cancer: racial disparities: are there any?. 2012 , 3, 467-80	92
1250	Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy. 2012 , 39, 1437-42	69
1249	Therapeutic Kinase Inhibitors. 2012 ,	1
1248	The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. 2012 , 18, 4406-14	144
1247	Prognostic and predictive factors for lung cancer. 2012 , 9, 112-121	26
1246	Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. 2012 , 18, 3470-7	46
1245	Worldwide overview of the current status of lung cancer diagnosis and treatment. 2012 , 136, 1478-81	47
1244	Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. 2012 , 185, 1316-22	196

1243	[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib]. 2012 , 66, 89-95	4
1242	[Personalized, individualized, stratified - Thoracic oncology quo vadis?]. 2012 , 66, 338-40	2
1241	The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation. 2012 , 19, 3337-52	30
1240	New approaches to targeted therapy in lung cancer. 2012 , 9, 72-3	19
1239	Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. 2012 , 16 Suppl 2, S55-60	3
1238	Targeted therapy for squamous cell lung cancer. 2012 , 1, 293-300	30
1237	Personalized therapy in endometrial cancer: challenges and opportunities. 2012 , 13, 1-13	52
1236	Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer. 2012 , 12, 237-46	11
1235	Potential of adaptive clinical trial designs in pharmacogenetic research. 2012 , 13, 571-8	13
1234	Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. 2012 , 109, 14476-81	208
1233	Management of advanced lung cancer in resource-constrained settings: a perspective from India. 2012 , 12, 1479-95	29
1232	Personalisiert, individualisiert, stratifiziert âThoraxonkologie quo vadis?. 2012 , 33, 360-362	
1231	Brain metastases from non-small-cell lung cancer: is there room for improvement?. 2012 , 12, 421-3	7
1230	Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?. 2012 , 12, 529-39	5
1229	Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. 2012 , 12, 107-23	41
1228	Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. 2012 , 8, 451-62	35
1227	EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. 2012 , 25, 548-55	65
1226	A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. 2012 , 18, 5682-9	109

1225	Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. 2012 , 30, 3417-20	48
1224	First-line therapy of mutated non-small cell lung cancer: an update. 2012 , 35, 293-9	1
1223	An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. 2012 , 23, 2914-2919	90
1222	Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence. 2012 , 2, 317-325	5
1221	Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. 2012 , 25, 1473-80	103
1220	Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules. 2012 , 106, 867-75	14
1219	Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. 2012 , 106, 666-72	28
1218	EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. 2012 , 17, 978-85	131
1217	Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. 2012 , 18, 1641-54	45
1216	Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. 2012 , 4, 19-29	68
1215	A framework for identification of actionable cancer genome dependencies in small cell lung cancer. 2012 , 109, 17034-9	138
1214	The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer. 2012 , 16 Suppl 2, S45-54	16
1213	Targeting the Met pathway in lung cancer. 2012 , 12, 519-28	24
1212	Bone matters in lung cancer. 2012 , 23, 2215-2222	44
1211	Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. 2012 , 17, 863-70	81
1210	EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC. 2012 , 18, 245-9	5
1209	HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer. 2012 , 11, 830-41	24
1208	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. 2012 , 17, 72-9	532

1207	Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. 2012 , 39, 9-28	25
1206	Therapeutic advances in non-small cell lung cancer. 2012 , 67, 1097-101	20
1205	The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer. 2012 , 6, 137-47	3
1204	CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib. 2012 , 8, 247-53	5
1203	Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies. 2012 , 12, 1299-312	3
1202	Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. 2012 , 5, 439-47	31
1201	Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases. 2012 , 2012, 354657	5
1200	Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. 2012 , 2012, 387172	11
1199	Oligometastatic disease at presentation or recurrence for nonsmall cell lung cancer. 2012 , 2012, 396592	16
1198	Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. 2012 , 2012, 817297	52
1197	Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?. 2012 , 2012, 838509	1
1196	Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care. 2012 , 2012, 921901	2
1195	The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors. 2012 , 58, 60-9	13
1194	Re-irradiation for metastatic brain tumors with whole-brain radiotherapy. 2012 , 42, 264-9	13
1193	Progression-free survival: meaningful or simply measurable?. 2012 , 30, 1030-3	223
1192	Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?. 2012 , 23 Suppl 10, x189-92	11
1191	Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials. 2012 , 35, 593-9	4
1190	Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. 2012 , 17, 555-68	34

1189	Lung Cancer and Other Pulmonary Neoplasms. 2012 , 1264-1272	3
1188	Randomized phase II trial designs with biomarkers. 2012 , 30, 3304-9	67
1187	Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. 2012 , 7, 856-65	33
1186	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. 2012 , 7, 115-21	180
1185	FGFR1 amplification in squamous cell carcinoma of the lung. 2012 , 7, 1775-1780	147
1184	EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 2012 , 7, 672-80	26
1183	Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months. 2012 , 35, 18-22	6
1182	[Individualized tumor therapy and status quo in melanoma]. 2012 , 35 Suppl 2, 2-6	
1181	Molecular characterization by immunocytochemistry of lung adenocarcinoma on cytology specimens. 2012 , 56, 603-10	19
1180	Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic non-small cell lung cancer. 2012 , 35, 600-3	12
1179	Semiautomated laser capture microdissection of lung adenocarcinoma cytology samples. 2012 , 56, 622-31	14
1178	EGFR gene mutation study in cytology specimens. 2012 , 56, 661-8	16
1177	Treatment of elderly patients with stage IV non-small-cell lung cancer. 2012 , 12, 111-20	5
1176	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. 2012 , 7, 1807-1814	454
1175	First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. 2012 , 10, 847-56	23
1174	Ten years of progress in non-small cell lung cancer. 2012 , 10, 292-5	32
1173	Ask the Experts: Lung cancer management: leaving behind the "one-fits-all" concept for a personalized approach. 2012 , 9, 367-372	
1172	Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. 2012 , 7, 1722-7	81

1171	Making the most of pathological specimens: molecular diagnosis in formalin-fixed, paraffin embedded tissue. 2012 , 13, 1475-87	30
1170	Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. 2012 , 7, 118-31	24
1169	Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. 2012 , 7, 775-6	20
1168	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. 2012 , 7, 348-54	170
1167	New driver mutations in non-small-cell lung cancer. 2012 , 2012, 108-110	
1166	Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. 2012 , 7, 1640-4	94
1165	Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer. 2012 , 2012, 111-113	
1164	Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer. 2012 , 7, 1522-7	19
1163	A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. 2012 , 7, 419-26	45
1162	Recent advances in lung cancer: summary of presentations from the 47 th annual meeting of the American Society of Clinical Oncology (ASCO) 2011. 2012 , 7, 260-5	3
1161	EGFR gene mutations: is it prognostic or predictive in surgically resected lung cancer?. 2012 , 7, 1739-1741	3
1160	p95HER2 truncated form in resected non-small cell lung cancer. 2012 , 7, 520-7	14
1159	Demographic profile of lung cancer patients at the Universitas Academic Hospital Bronchoscopy Unit in Bloemfontein. 2012 , 27, 130-132	
1158	Targeted therapy in non-small cell lung cancer. 2012 , 8, 206-215	1
1157	Applying biomarker testing to clinical practice in lung cancer. 2012 , 1, 145-154	
1156	EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing. 2012 , 20, 356-62	9
1155	Targeted therapy for lung cancer. 2012 , 23, 1016-21	20
1154	Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors. 2012 , 24, 123-9	24

1153	Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements. 2012 , 2, 895-907	1
1152	Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced non-small cell lung cancer. 2012 , 24, 130-6	17
1151	Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. 2012 , 3, 207-213	15
1150	Update on HER1-3 in advanced non-small-cell lung cancer. 2012 , 7, S369-71	4
1149	Lung adenocarcinoma. 2012 , 136-165	
1148	Phase II randomized trial of erlotinib or vinorelbine in chemotherapy-naïve, advanced, non-small cell lung cancer patients aged 70 years or older. 2012 , 7, 412-8	50
1147	Non-small cell lung cancer. 2012 , 10, 1236-71	270
1146	Value-based insurance design: aligning incentives, benefits, and evidence in oncology. 2012 , 10, 18-23	20
1145	[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 3) Non-small cell lung cancer]. 2012 , 101, 2520-5	1
1144	MET signaling: novel targeted inhibition and its clinical development in lung cancer. 2012 , 7, 459-67	78
1143	Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC. 2012 , 3, 1064-1068	4
1142	Optimizing treatment outcomes in patients at risk for chemotherapy-induced nausea and vomiting. 2012 , 16, 309-13	8
1141	Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors. 2012 , 7, 40-8	36
1140	Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. 2012 , 3, 1288-1292	14
1139	Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer. 2012 , 4, 89-93	23
1138	[EGFR/HER1: a target life]. 2012 , 99, 181-9	2
1137	Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. 2012 , 7, 382-5	182
1136	Maintenance therapy for advanced non-small-cell lung cancer: a pilot study on patients' perceptions. 2012 , 7, 1291-5	23

1135	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. 2012 , 7, 1815-1822	128
1134	First- and second-line treatment of non-small-cell lung cancer patients with EGFR mutation-positive tumors. 2012 , 1, 201-217	
1133	[Which platform to support a personalized lung cancer treatment?]. 2012 , 99, 529-34	1
1132	Obstructive lung disease does not increase lung cancer mortality among female never-smokers in Hong Kong. 2012 , 16, 546-52	6
1131	Molecular-Based Decision Making for Personalized Cancer Management. 2012 ,	
1130	EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. 2012 , 7, 434-42	15
1129	Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans. 2012 , 2012, 110-111	
1128	Mutation and expression of multiple treatment response-related genes in a population with locally advanced non-small cell lung cancer. 2012 , 3, 415-420	8
1127	Ask the Experts: EGFR mutation and non-small-cell lung cancer: EGFR test, cost and quality of life. 2012 , 1, 169-172	
1126	Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation. 2012 , 7, 1218-27	14
1125	Primary treatment of advanced non-small-cell lung cancer: role of monoclonal antibodies. 2012 , 1, 219-225	
1124	Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. 2012 , 7, 1594-601	32
1123	Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. 2012 , 7, 122-7	27
1122	Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation. 2012 , 7, 49-56	33
1121	Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors. 2012 , 4, 865-867	11
1120	A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. 2012 , 7, 1602-8	110
1119	Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. 2012 , 7, 1830-1844	17
1118	Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. 2012 , 7, 1369-81	63

1117	Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. 2012 , 7, 993-1000	25
1116	Progress in standard of care therapy and modest survival benefits in the treatment of non-small cell lung cancer patients in the Netherlands in the last 20 years. 2012 , 7, 291-8	46
1115	EGFR array: uses in the detection of plasma EGFR mutations in non-small cell lung cancer patients. 2012 , 7, 1131-40	41
1114	Genomic copy number alterations associated with the early brain metastasis of non-small cell lung cancer. 2012 , 41, 2013-20	18
1113	EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. 2012 , 7, 98-104	76
1112	Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). 2012 , 7, 1490-502	65
1111	Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with non-small cell lung cancer. 2012 , 4, 226-230	12
1110	Anti-MET-targeted therapy for NSCLC: has it come of age?. 2012 , 2, 1053-1056	
1109	Genetic changes in squamous cell lung cancer: a review. 2012 , 7, 924-33	98
1108	Targeted therapies in small cell lung cancer. 2013 , 5, 3-11	22
1107	First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. 2012 , 7, 1417-22	109
1106	Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma. 2012 , 29, 3169-75	4
1105	Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. 2012 , 17, 1351-75	175
1104	Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. 2012 , 18, 3737-42	64
1103	Non-small cell lung cancer: One size doesn't fit all. 2012 , 8, 211-2	
1102	The role of molecular analyses in the era of personalized therapy for advanced NSCLC. 2012 , 76, 131-7	26
1101	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. 2012 , 70, 315-20	12
1100	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. 2012 , 2, 934-47	212

1099	The paradigm of personalized therapy in oncology. 2012 , 16 Suppl 1, S7-16	16
1098	EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. 2012 , 33, 2061-8	24
1097	Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. 2012 , 103, 1946-54	52
1096	Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. 2012 , 61, 1017-25	79
1095	EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. 2012 , 77, 2-8	57
1094	Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. 2012 , 52, 549-73	82
1093	The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP). 2012 , 77, 183-91	13
1092	Advances in treatment of lung cancer with targeted therapy. 2012 , 136, 504-9	57
1091	Lung cancer genotype-based therapy and predictive biomarkers: present and future. 2012 , 136, 1482-91	33
1090	RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. 2012 , 75, 306-12	37
1089	Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. 2012 , 70, 707-16	31
1088	Lung Cancer Therapy Annual 7. 2012 ,	0
1087	Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. 2012 , 23, 1738-43	42
1086	Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. 2012 , 107, 1745-53	20
1085	The transcriptional landscape and mutational profile of lung adenocarcinoma. 2012 , 22, 2109-19	435
1084	It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. 2012 , 11, 2549-55	39
1083	Clinical and economic review of erlotinib in non-small-cell lung cancer. 2012 , 12, 411-23	8
1082	EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. 2012 , 8, 1015-29	15

1081	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. 2012 , 13, e23-31	401
1080	Mind over menopausal symptoms in women with breast cancer. 2012 , 13, 227-9	1
1079	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. 2012 , 13, 239-46	3985
1078	Beyond first-line NSCLC therapy: chemotherapy or erlotinib?. 2012 , 13, 225-7	11
1077	Optimising therapy for EGFR-addicted NSCLC: just the start. 2012 , 13, 216-7	2
1076	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. 2012 , 13, 539-48	331
1075	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. 2012 , 13, 528-38	777
1074	Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. 2012 , 13, 466-75	189
1073	A new generation of EGFR tyrosine-kinase inhibitors in NSCLC. 2012 , 13, 442-3	11
1072	Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer. 2012 , 13, 369-74	9
1071	Companion Diagnostics and the DrugâDiagnostic Codevelopment Model. 2012 , 73, 390-397	9
1070	Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. 2012 , 51, 607-17	34
1069	Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. 2012 , 461, 629-38	27
1068	Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib. 2012 , 138, 1963-9	10
1067	Personalized medicine using DNA biomarkers: a review. 2012 , 131, 1627-38	131
1066	A new convenient technique for making cell blocks. 2012 , 350, 395-400	8
1065	Directed Therapies in Lung Cancer: New Hope?. 2012 , 48, 367-371	1
1064	Directed therapies in lung cancer: new hope?. 2012 , 48, 367-71	5

1063	SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. 2012 , 76 Spec No., 91-101	49
1062	[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology]. 2012 , 106, 11-22	7
1061	Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case-control study. 2012 , 33, 1341-8	15
1060	Molecular Pathology of Non-Small Cell Lung Cancer. 2012 , 5, 903-18	2
1059	Traitement du cancer bronchique non ^petites cellules au stade avanc^chez le sujet b: 2012 , 4, 621-628	
1058	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. 2012 , 58, 263-8	4
1057	La maladie oligom^tastatique dans le cancer bronchique non ^petites cellules. 2012 , 4, 639-644	
1056	Molecular markers for incidence, prognosis, and response to therapy. 2012 , 21, 161-75	6
1055	[EGFR activating mutation in lung adenocarcinoma: risk factor of thromboembolic event?]. 2012 , 29, 1137-40	
1054	Prise en charge th^apeutique des cancers bronchiques non ^petites cellules m^tastatiques mut^s pour l^EGFR. 2012 , 4, 583-598	0
1053	The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer. 2012 , 5 Suppl 1, S50-60	16
1052	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. 2012 , 58, 263-268	
1051	Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer. 2012 ,	
1050	Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. 2012 , 72, 4154-64	105
1049	Vandetanib for the treatment of lung cancer. 2012 , 21, 1211-21	5
1048	The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. 2012 , 106, 1100-6	79
1047	Targeted therapy of non-small-cell lung carcinoma. 2012 , 6, 41-56	3
1046	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. 2012 , 39, 172-9	31

1045	Disparities in subgroup populations enrolled in lung cancer trials. 2012 , 6, 163-72	
1044	Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. 2012 , 19 Suppl 3, S347-54	45
1043	Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens. 2012 , 186, 1160-7	36
1042	Exhaled breath volatile organic compound biomarkers in lung cancer. 2012 , 6, 027106	41
1041	High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma. 2012 , 18, 1760-8	51
1040	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. 2012 , 18, 938-44	124
1039	Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). 2012 , 30, 1114-21	205
1038	International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. 2012 , 30, 2829-36	158
1037	Clinical trials and biomarker research on lung cancer in China. 2012 , 16 Suppl 1, S45-50	18
1036	Translating genomic information into clinical medicine: lung cancer as a paradigm. 2012 , 22, 2101-8	64
1035	Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. 2012 , 21, 147-51	16
1034	Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors. 2012 , 8, 2645-56	9
1033	Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. 2012 , 106, 473-92	8
1032	Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. 2012 , 13, 935-45	23
1031	Cancer biomarkers: selecting the right drug for the right patient. 2012 , 11, 201-14	202
1030	Integrating multiple social statuses in health disparities research: the case of lung cancer. 2012 , 47, 1255-77	93
1029	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation. 2012 , 2, 922-33	528
1028	Lung Cancer. 2012 , 776-787	

1027	Lung Cancer: Treatment. 2012 , 801-809	
1026	The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation. 2012 , 72, 3764-74	78
1025	Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. 2012 , 30, 3640-7	146
1024	Two sides of the same coin: EGFR exon 19 deletions and insertions in lung cancer. 2012 , 18, 1490-2	10
1023	EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. 2012 , 18, 1790-7	115
1022	Translating cancer genomes sequencing revolution into surgical oncology practice. 2012 , 173, 365-9	6
1021	EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis. 2012 , 314, 63-72	30
1020	Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. 2012 , 38, 63-7	22
1019	Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. 2012 , 38, 36-53	48
1018	Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). 2012 , 38, 173-84	26
1017	Problems involved in the clinical trials for non-small cell lung carcinoma. 2012 , 38, 194-202	6
1016	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. 2012 , 38, 416-30	97
1015	The genetic basis for cancer treatment decisions. 2012 , 148, 409-20	242
1014	Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. 2012 , 48, 61-7	27
1013	A phase II study of ^{18}F -fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks. 2012 , 48, 68-74	24
1012	Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. 2012 , 48, 1096-107	33
1011	ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. 2012 , 48, 961-73	71
1010	Lung cancer in never smokers--a review. 2012 , 48, 1299-311	280

1009	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. 2012 , 30, 3077-83	154
1008	Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. 2012 , 30, 3084-92	214
1007	Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. 2012 , 30, 3330-6	38
1006	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. 2012 , 30, 3002-11	193
1005	Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). 2012 , 23, 2253-2258	37
1004	Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial. 2012 , 12, 185	13
1003	Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors. 2012 , 12, 241	54
1002	Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer. 2012 , 12, 568	30
1001	Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands. 2012 , 10, 108	10
1000	Membrane-bound estrogen receptor- β expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients. 2012 , 10, 141	10
999	Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. 2012 , 10, 28	96
998	Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis. 2012 , 5, 62	25
997	Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer. 2012 , 3, 6	2
996	A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. 2012 , 7, e43842	72
995	Therapeutic Drug Monitoring of Selected Anticancer Drugs. 2012 , 291-321	1
994	Role of randomized phase III trials in an era of effective targeted therapies. 2011 , 9, 208-14	39
993	Treatment of lung cancer. 2012 , 50, 961-74	62
992	Targeting the EGFR signaling pathway in cancer therapy. 2012 , 16, 15-31	512

991	First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients. 2012 , 13, 1389-96	8
990	Role of chemotherapy on brain metastasis. 2012 , 25, 110-4	8
989	EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. 2012 , 83, 248-56	36
988	First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. 2012 , 6, 337-45	40
987	The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. 2012 , 3, 334-340	35
986	Discordance of epidermal growth factor receptor mutations between primary tumors and corresponding mediastinal nodal metastases in patients operated on for stage N2 non-small cell lung cancer. 2012 , 3, 313-319	5
985	Management of small cell lung cancer: recent developments for optimal care. 2012 , 72, 471-90	52
984	Genomic biomarkers for patient selection and stratification: the cancer paradigm. 2012 , 4, 2499-511	7
983	Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. 2012 , 30, 17-34	26
982	CT fluoroscopy-guided percutaneous osteoplasty for the treatment of osteolytic lung cancer bone metastases to the spine and pelvis. 2012 , 23, 1135-42	26
981	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. 2012 , 483, 613-7	361
980	Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. 2012 , 55, 10685-99	37
979	Clinical results with EGFR inhibitors in NSCLC and their use in the treatment of metastatic disease. 2012 , 34-43	
978	Genetic insight and therapeutic targets in squamous-cell lung cancer. 2012 , 31, 4811-4	24
977	RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. 2012 , 39, 677-84	37
976	First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. 2012 , 13, 1161-70	142
975	Who should receive EGFR tyrosine-kinase inhibitors?. 2012 , 13, 1074-6	2
974	MDM2 inhibition in liposarcoma: a step in the right direction. 2012 , 13, 1070-1	15

973	Predicting who will have asthma at school age among preschool children. 2012 , 130, 325-31	86
972	Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer. 2012 , 13, 385-90	15
971	Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. 2012 , 13, 334-9	40
970	A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer. 2012 , 13, 432-41	16
969	Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and inpatient tumor heterogeneity. 2012 , 13, 321-5	20
968	EGFR inhibition and other targeted therapies in NSCLC. 2012 , 9, S30-S34	
967	Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. 2012 , 83, 407-21	120
966	Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. 2012 , 84, 47-58	32
965	Cancer chemotherapy: a critical analysis of its 60 years of history. 2012 , 84, 181-99	60
964	Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. 2012 , 38, 626-40	67
963	Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: current status and future challenges. 2012 , 38, 861-7	18
962	Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials. 2012 , 38, 807-14	17
961	Ethnic variation in response to EGFR inhibitors. 2012 , 9, e61-e66	1
960	Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: potentials as therapeutic target. 2012 , 48, 991-996	27
959	[Targeted agents in the treatment of lung cancer]. 2012 , 60, 246-53	0
958	Recomendaciones para la determinaci3n de biomarcadores en el carcinoma de pulm3n no microc3tico avanzado. Consenso nacional de la Sociedad Espa3ola de Anatom3a Patol3gica y de la Sociedad Espa3ola de Oncolog3a M3dica. 2012 , 45, 14-28	6
957	Consenso Nacional SEAP-SEOM sobre biomarcadores en el c3ncer de pulm3n no microc3tico avanzado. 2012 , 45, 1-3	
956	Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. 2012 , 75, 82-8	83

955	Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. 2012 , 75, 89-94	52
954	Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. 2012 , 75, 321-5	66
953	Are EUS-FNA and EBUS-TBNA specimens reliable for subtyping non-small cell lung cancer?. 2012 , 76, 46-50	23
952	Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. 2012 , 76, 78-83	26
951	Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care. 2012 , 75, 269-74	8
950	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. 2012 , 76, 1-18	171
949	Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. 2012 , 76, 235-41	25
948	Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. 2012 , 76, 292-9	45
947	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. 2012 , 76, 403-9	130
946	Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung. 2012 , 76, 423-30	31
945	Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. 2012 , 76, 387-92	120
944	Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. 2012 , 76, 123-7	213
943	Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. 2012 , 77, 121-7	60
942	Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. 2012 , 77, 224-31	108
941	Retrospective study of erlotinib in patients with advanced squamous lung cancer. 2012 , 77, 128-33	28
940	Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. 2012 , 77, 346-52	22
939	Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. 2012 , 77, 339-45	27
938	EGFR mutations as a predictive marker of cytotoxic chemotherapy. 2012 , 77, 433-7	19

937	Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. 2012 , 77, 299-305	48
936	Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. 2012 , 77, 460-3	71
935	Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature. 2012 , 77, 464-8	23
934	Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials. 2012 , 77, 537-44	29
933	Targeted therapy of metastatic NSCLC in clinical setting at US. 2012 , 77, S23-S24	
932	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. 2012 , 77, 556-60	247
931	A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. 2012 , 78, 57-62	8
930	Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. 2012 , 78, 81-6	59
929	Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. 2012 , 77, 475-81	10
928	Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. 2012 , 78, 100-6	67
927	Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). 2012 , 78, 239-44	26
926	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. 2012 , 6, 15-26	62
925	Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design. 2012 , 6, 196-203	22
924	Practical perspectives of personalized healthcare in oncology. 2012 , 29, 656-64	8
923	Do companion diagnostics make economic sense for drug developers?. 2012 , 29, 695-708	9
922	Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. 2012 , 72 Suppl 1, 28-36	54
921	Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. 2012 , 186, 1180-8	137
920	EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. 2012 , 12, 1429-35	32

919	Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. 2012 , 13, 516-26	11
918	Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. 2012 , 64, 155-60	46
917	Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy. 2012 , 29, 1629-37	3
916	Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. 2012 , 29, 1656-62	99
915	Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. 2012 , 29, 1599-605	3
914	Cancfologie. 2012 , 4, 740-745	
913	The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma. 2012 , 14, 1075-86	13
912	Les biomarqueurs ^rechercher en 2012 et dans le futur proche dans les cancers bronchiques non ^ petites cellules (CBNPC). 2012 , 4, 578-582	
911	Lungenkrebs: Operation, Strahlentherapie und systemische Therapie. 2012 , 7, 133-139	
910	Lung Cancer. 2012 , 35-61	
909	Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation. 2012 , 72 Suppl 1, 3-10	5
908	Targeting the epidermal growth factor receptor in solid tumor malignancies. 2012 , 26, 83-99	27
907	Personalized cancer therapy for stage IV non-small cell lung cancer: Combined use of active hexose correlated compound and genistein concentrated polysaccharide. 2012 , 1, 39-44	3
906	First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. 2012 , 30, 1122-8	607
905	Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. 2012 , 30, 433-40	420
904	Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. 2012 , 3, 713-717	11
903	Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. 2012 , 4, 173-81	14
902	Genomics Applications for the Developing World. 2012 ,	6

901	Cancer Epigenetics. 2012,	4
900	Molecular Pathology of Lung Cancer. 2012,	5
899	Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. 2012, 12, 612	34
898	Designs for Clinical Trials. 2012,	3
897	Personalizing lung cancer prevention through a reverse migration strategy. 2013, 329, 221-40	4
896	Tyrosine kinase inhibitors in lung cancer. 2012, 26, 589-605, viii	24
895	DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer. 2012, 31, 80	30
894	Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer. 2012, 31, 77	18
893	Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR. 2012, 31, 65	27
892	A novel classification of lung cancer into molecular subtypes. 2012, 7, e31906	82
891	Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. 2012, 7, e37775	50
890	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. 2012, 7, e40109	136
889	Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. 2012, 7, e44225	25
888	Molecular Pathogenesis of Non-Small Cell Lung Carcinomas. 2012, 11, 12	4
887	Non-small cell lung cancer: the era of targeted therapy. 2012, 3, 31-41	6
886	Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. 2012, 2, 35-49	6
885	Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System. 2012, 2, 77-92	2
884	New EGFR-TKI: A case report of recurrent lung adenocarcinoma successfully treated with icotinib. 2012, 98, e102-e104	3

883	The Role of Tyrosine Kinases in the Pathogenesis and Treatment of Lung Disease. 2012,	2
882	Braf and erbB2 mutations correlate with smoking status in lung cancer patients. 2012, 3, 771-775	16
881	Tools to Simulate Realistic Censored Survival-Time Distributions. 2012, 12, 639-654	9
880	Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats. 2012, 59, 174-85	11
879	Pharmacogenetics: transforming clinical medicine. 2012, 42, 244-7	2
878	Therapeutic targeting of the epidermal growth factor receptor in human cancer. 2012, 17, 31-50	51
877	The place of TKI in the treatment of EGFR mutation-positive lung cancer. 2012, 2,	
876	Adenocarcinoma. 122-144	
875	Final Analysis of Overall Survival (OS) in the IPASS, an International Multicenter Phase III Study on Gefitinib and Carboplatin/Paclitaxel for Treatment-na ^{ive} NSCLC Patients. 2012, 52, 153-160	2
874	EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. 2012, 53, 1128-35	19
873	Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. 2012, 16, 401-6	5
872	A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer. 2012, 3, 53-59	1
871	Improving the quality of abstract reporting for economic analyses in oncology. 2012, 19, e428-35	2
870	K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. 2012, 2012, 837306	22
869	A modified extraction method of circulating free DNA for epidermal growth factor receptor mutation analysis. 2012, 53, 132-7	27
868	Emerging treatment options for patients with recurrent advanced thymic epithelial tumors. 2012, 5, 177-84	1
867	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Inhibitors and Overcoming Strategies in Lung Cancer. 2012, 11, 59	2
866	Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. 2012, 3, 7-13	22

865	Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. 2012 , 53, 931-9	16
864	MET targeted therapy for lung cancer: clinical development and future directions. 2012 , 3, 53-67	4
863	Application of glycoproteomics for the discovery of biomarkers in lung cancer. 2012 , 6, 244-56	24
862	Phosphorylation events during viral infections provide potential therapeutic targets. 2012 , 22, 166-81	59
861	On Bayesian methods of exploring qualitative interactions for targeted treatment. 2012 , 31, 3693-707	10
860	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. 2012 , 30, 777-82	355
859	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. 2012 , 30, 2063-9	197
858	Molecular pathology of lung cancer: key to personalized medicine. 2012 , 25, 347-69	171
857	Cancer genomics: technology, discovery, and translation. 2012 , 30, 647-60	134
856	ALKoma: a cancer subtype with a shared target. 2012 , 2, 495-502	141
855	Circumventing cancer drug resistance in the era of personalized medicine. 2012 , 2, 214-26	348
854	Combinatorial drug therapy for cancer in the post-genomic era. 2012 , 30, 679-92	670
853	Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. 2012 , 489, 155-9	260
852	Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. 2012 , 69, 1289-99	35
851	The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. 2012 , 30, 3012-9	125
850	Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. 2012 , 51, 925-32	20
849	Novel molecular targeted therapies for refractory thyroid cancer. 2012 , 34, 736-45	19
848	Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. 2012 , 130, 2445-54	54

847	A novel treatment strategy for EGFR mutant NSCLC with T790M-mediated acquired resistance. 2012 , 131, 970-9	7
846	Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. 2012 , 131, E822-9	98
845	Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. 2012 , 131, E227-35	68
844	Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. 2012 , 118, 4502-11	202
843	p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients. 2012 , 118, 5015-25	16
842	Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. 2012 , 118, 5588-94	42
841	Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. 2012 , 118, 6234-42	72
840	Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. 2012 , 118, 5840-7	44
839	The diagnostic value of cell block as an adjunct to liquid-based cytology of bronchial washing specimens in the diagnosis and subclassification of pulmonary neoplasms. 2012 , 120, 134-41	29
838	Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. 2012 , 120, 185-95	78
837	Targeting ALK in neuroblastoma--preclinical and clinical advancements. 2012 , 9, 391-9	120
836	Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. 2012 , 30, 433-46	47
835	Management of hepatocellular carcinoma: beyond sorafenib. 2012 , 14, 257-66	22
834	Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications. 2012 , 13, 789-802	31
833	Management of non-small cell lung cancer with oligometastasis. 2012 , 14, 333-41	29
832	Comparative screening of K-ras mutations in colorectal cancer and lung cancer patients using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing. 2012 , 62, 415-20	12
831	Colonic metastasis from primary lung adenocarcinoma: case report and review of the literature. 2012 , 29, 644-7	5
830	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). 2012 , 14, 338-49	29

829	A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. 2012 , 69, 1241-6	38
828	The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib. 2012 , 69, 1407-12	8
827	[Non-small cell lung cancer. Subtyping and predictive molecular marker investigations in cytology]. 2012 , 33, 301-7	6
826	EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma. 2012 , 138, 1421-5	19
825	Rôle de l'évaluation gériatrique dans le traitement des CBNPC au stade métastatique. 2012 , 14, 289-296	
824	Palliativ intendierte First-line-Chemotherapie des metastasierten nichtkleinzelligen Lungenkarzinoms. 2012 , 9, 115-119	
823	Factors associated with long-term survival of patients with advanced non-small cell lung cancer. 2012 , 17, 134-42	36
822	Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. 2012 , 271, 111-21	147
821	Personalized medicine for lung cancer: new challenges for pathology. 2012 , 60, 531-46	73
820	SnapShot: non-small cell lung cancer. 2012 , 21, 448.e2	140
819	Smoking history as a predictive factor of treatment response in advanced non-small-cell lung cancer: a systematic review. 2012 , 13, 239-51	24
818	A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. 2012 , 13, 129-35	7
817	Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. 2012 , 13, 107-14	104
816	Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors. 2012 , 13, 267-79	17
815	Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). 2012 , 13, 252-66	95
814	Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. 2012 , 13, 123-8	9
813	Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials. 2012 , 24, 396-401	8
812	Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions. 2012 , 82, 338-60	7

811	Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges. 2012 , 83, 130-44	22
810	Relevance of systems pharmacology in drug discovery. 2012 , 17, 665-70	34
809	Exploiting genetic complexity in cancer to improve therapeutic strategies. 2012 , 17, 188-93	12
808	Stratified medicine for cancer therapy. 2012 , 17, 261-8	5
807	Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer. 2012 , 66, 748-752	19
806	Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib. 2012 , 8, 267-74	2
805	Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. 2012 , 8, 232-43	33
804	EBUS and EUS guided fine needle aspirations for molecular diagnostic analysis in lung cancer. 2012 , 3, 201-206	3
803	Comparison of epidermal growth factor receptor mutation analysis results between surgically resected primary lung cancer and metastatic lymph nodes obtained by endobronchial ultrasound-guided transbronchial needle aspiration. 2012 , 3, 262-268	4
802	Management of lung cancer. 2012 , 40, 202-207	
801	The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases. 2012 , 23, 229-36	43
800	Molecular diagnosis on tissues and cells: how it affects training and will affect practice in the future. 2012 , 23, 286-94	10
799	Fine needle aspiration of non-small cell lung cancer: current state and future perspective. 2012 , 23, 213-9	27
798	Targeted therapy of hepatocellular carcinoma: present and future. 2012 , 27, 862-72	63
797	Matrix-assisted laser desorption/ionization mass spectrometry reveals decreased calcylcin expression in small cell lung cancer. 2012 , 62, 28-35	6
796	The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer. 2012 , 17, 247-60	20
795	Biomarkers and transcriptome profiling of lung cancer. 2012 , 17, 620-6	18
794	A retrospective analysis comparing the safety and efficacy of chemotherapy in elderly and non-elderly non-small-cell lung cancer patients. 2012 , 12, 499-505	2

793	Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma. 2012 , 12, 87	20
792	Translatability scoring in drug development: eight case studies. 2012 , 10, 39	30
791	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. 2012 , 118, 729-39	114
790	Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. 2012 , 118, 1032-9	52
789	Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. 2012 , 130, 1733-44	65
788	Prädiktive Biomarker als Entscheidungsgrundlage für die onkologische Therapie. 2012 , 27, 27-32	0
787	Molekularpathologische Grundlagen für die Therapie des NSCLC. 2012 , 7, 4-11	
786	Qualitätssicherung in der Onkologie. 2012 , 7, 11-11	
785	The "Virtual Patient" System: modeling cancer using deep sequencing technologies for personalized cancer treatment. 2012 , 7, 55-62	7
784	A potential human hepatocellular carcinoma inhibitor from Bauhinia purpurea L. seeds: from purification to mechanism exploration. 2012 , 86, 293-304	12
783	Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors. 2012 , 69, 333-9	10
782	Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. 2012 , 69, 273-80	9
781	Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. 2012 , 69, 289-99	44
780	A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. 2012 , 131, 899-906	22
779	Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. 2012 , 39, 4971-9	30
778	Diagnostik und Staging beim fortgeschrittenen Lungenkarzinom. 2012 , 9, 9-14	
777	Erstlinientherapie beim fortgeschrittenen nichtkleinzelligen Lungenkarzinom. 2012 , 9, 22-27	
776	Das fortgeschrittene Lungenkarzinom. 2012 , 9, 49-54	

775	Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma. 2012 , 138, 285-91	1
774	Evaluation of EGFR mutation status in cytology specimens: an institutional experience. 2013 , 41, 316-23	49
773	Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment. 2013 , 35, 294-306	17
772	SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma. 2013 , 132, 459-71	21
771	Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. 2013 , 41, 417-24	30
770	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. 2013 , 119, 356-62	122
769	A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma. 2013 , 11, 96	16
768	High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR. 2013 , 11, 90	26
767	Cancer Pain. 2013 ,	8
766	Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. 2013 , 8, 27	24
765	Origin of ovarian cancer: molecular profiling. 2013 , 63, 152-7	7
764	Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. 2013 , 119, 3761-8	37
763	EGFR mutations in malignant pleural effusions from lung cancer. 2013 , 2, 79-87	8
762	Tailored management of advanced squamous non-small cell lung cancer (NSCLC). 2013 , 2, 10-16	
761	Advanced non-squamous non-small-cell lung cancer: who and when should be biologically screened today? Tomorrow?. 2013 , 2, 17-21	1
760	Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. 2013 , 119, 3043-51	18
759	Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. 2013 , 14, 322-32	84
758	Management of Lung Cancer in Older People. 2013 ,	

757	The impact of genomic changes on treatment of lung cancer. 2013 , 188, 770-5	76
756	EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. 2013 , 9, 991-1003	6
755	Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants. 2013 , 125, 8545-8548	0
754	Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design. 2013 , 56, 5757-72	17
753	Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs. 2013 , 1, 67-76	
752	Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study. 2013 , 13, 354	35
751	Impact of genetic targets on cancer therapy. Forward. 2013 , 779, v-vi	1
750	Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes. 2013 , 104, 904-11	44
749	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. 2013 , 14, 981-8	402
748	Targeted therapies: Time to shift the burden of proof for oncogene-positive cancer?. 2013 , 10, 492-3	4
747	Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?. 2013 , 15, 959-64	2
746	Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients. 2013 , 139, 409-17	10
745	Nutzenbewertung personalisierter Interventionen: Methodische Herausforderungen und Lösungsansätze. 2013 , 25, 173-182	6
744	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. 2013 , 21, 3243-54	37
743	Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. 2013 , 21, 1167-74	53
742	Side Effects of Medical Cancer Therapy. 2013 ,	2
741	Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer. 2013 , 19, 833-8	22
740	Recommendations of the Austrian Working Group on Lung Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer. 2013 , 6, 83-91	3

739	Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer. 2013 , 31, 1275-82	28
738	Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. 2013 , 319, 417-23	20
737	MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. 2013 , 7, 112-20	61
736	Management of non-small-cell lung cancer: recent developments. 2013 , 382, 709-19	563
735	Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. 2013 , 8, 107-16	7
734	Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). 2013 , 8, 27-33	82
733	Clinical meta-analyses of targeted therapies in adenocarcinoma. 2013 , 8, 35-45	3
732	ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. 2013 , 8, 55-67	66
731	Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. 2013 , 109, 827-35	79
730	Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. 2013 , 62, 309-20	38
729	Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. 2013 , 71, 705-11	6
728	[Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing]. 2013 , 34, 310-7	5
727	New Advances in the Precision Medicine of Lung Cancer. 2013 , 1, 1-8	3
726	Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. 2013 , 52, 593-609	64
725	First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. 2013 , 73, 357-69	12
724	60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. 2013 ,	7
723	The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. 2013 , 96, 962-8	69
722	Lung cancer in never smokers: disease characteristics and risk factors. 2013 , 88, 494-503	91

721	EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. 2013 , 109, 1821-8	92
720	Molecular Surgical Pathology. 2013 ,	18
719	Tumor Ablation. 2013 ,	7
718	A linear polyethylenimine mediated siRNA-based therapy targeting human epidermal growth factor receptor in SPC-A1 xenograft mice. 2013 , 1, 2	3
717	Clinical perspective of afatinib in non-small cell lung cancer. 2013 , 81, 155-61	43
716	Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. 2013 , 119, 2754-64	91
715	Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. 2013 , 82, 420-5	32
714	Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77. 2013 , 14, 224-9	10
713	United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. 2013 , 37, 110-44	40
712	A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. 2013 , 82, 299-304	26
711	Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma. 2013 , 80, 159-64	25
710	A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. 2013 , 82, 461-8	4
709	A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. 2013 , 82, 276-81	28
708	Targeting receptor tyrosine kinases in solid tumors. 2013 , 22, 685-703	7
707	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. 2013 , 80, 120-30	40
706	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. 2013 , 39, 839-50	84
705	Clinical outcomes of biological effective dose-based fractionated stereotactic radiation therapy for metastatic brain tumors from non-small cell lung cancer. 2013 , 85, 984-90	25
704	Ocular metastasis of lung adenocarcinoma with ELM4-ALK translocation: A case report with a review of the literature. 2013 , 27, 187-92	12

703	Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). 2013 , 82, 115-20	8
702	The quest to overcome resistance to EGFR-targeted therapies in cancer. 2013 , 19, 1389-400	684
701	CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives. 2013 , 80, 242-8	53
700	[Smoking cessation therapy in thoracic oncology]. 2013 , 30, 696-705	0
699	Biologic approaches to drug selection and targeted therapy: hype or clinical reality?. 2013 , 23, 421-8	3
698	[Characterization of principal predictive biomarkers of targeted therapies in thoracic cancer]. 2013 , 71, 369-75	
697	C�ncer de pulm�n no microc�tico. 2013 , 11, 1429-1440	
696	Targeted therapy for NSCLC with driver mutations. 2013 , 13, 1401-12	33
695	Management strategy of pulmonary nodule in 2013. 2013 , 94, 1081-94	32
694	Selection and adaptation during metastatic cancer progression. 2013 , 501, 365-72	200
693	Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. 2013 , 49, 3111-21	58
692	Bringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology. 2013 , 9, 35-44	5
691	Crizotinib in the treatment of non--small-cell lung cancer. 2013 , 14, 473-80	32
690	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. 2013 , 13, 1207-18	10
689	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 2013 , 8, 1381-97	6
688	Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. 2013 , 19, 1469-1472	420
687	Genetic alterations defining NSCLC subtypes and their therapeutic implications. 2013 , 82, 179-89	189
686	Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. 2013 , 24, 2080-7	92

685	Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. 2013 , 36, 439-48	33
684	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. 2013 , 15, 977-84	17
683	Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements. 2013 , 12, 366-74	9
682	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. 2013 , 5, 216ra177	313
681	Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?. 2013 , 66, 839-46	23
680	Clinical application of amplicon-based next-generation sequencing in cancer. 2013 , 206, 413-9	85
679	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. 2013 , 19, 2240-7	1655
678	Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. 2013 , 73, 5195-205	136
677	Fibroblast growth factor receptor-3 in urothelial tumorigenesis. 2013 , 31, 303-11	44
676	CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. 2013 , 109, 2803-9	16
675	Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703. 2013 , 51, 28-34	9
674	ROS1 fusions in Chinese patients with non-small-cell lung cancer. 2013 , 24, 1822-1827	65
673	Lung Cancer Imaging. 2013 ,	1
672	Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine. 2013 , 14, 609-26	14
671	Strategies for improving outcomes in NSCLC: a look to the future. 2013 , 82, 375-82	26
670	Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. 2013 , 88, 477-93	53
669	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. 2013 , 31, 3133-40	226
668	A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. 2013 , 14, 215-23	37

667	Statistical and practical considerations for clinical evaluation of predictive biomarkers. 2013 , 105, 1677-83	91
666	Bioinformatics for Diagnosis, Prognosis and Treatment of Complex Diseases. 2013 ,	
665	HER2 and lung cancer. 2013 , 13, 1219-28	50
664	KRAS mutations in lung cancer. 2013 , 14, 205-14	149
663	Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. 2013 , 31, 1587-91	10
662	Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. 2013 , 72, 1125-32	44
661	Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. 2013 , 32, 50	85
660	[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer]. 2014 , 17, 391-400	1
659	First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?. 2012 , 1, 219-23	4
658	Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents. 2015 , 3, 81	9
657	[Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation]. 2011 , 14, 880-4	2
656	Biomarkers in the selection of maintenance therapy in non-small cell lung cancer. 2012 , 1, 96-8	9
655	EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?. 2012 , 1, 269-75	5
654	Cutaneous metastasis as an initial presentation of lung adenocarcinoma with KRAS mutation: a case report and literature review. 2014 , 1, 6	3
653	Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. 2011 , 36, 263-79	14
652	Next-generation sequencing for cancer diagnostics: a practical perspective. 2011 , 32, 177-95	246
651	Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?. 2010 , 2, 189-91	1
650	New molecular targeted therapies for advanced non-small-cell lung cancer. 2011 , 3, 30-56	26

649	Post-study therapy as a source of confounding in survival analysis of first-line studies in patients with advanced non-small-cell lung cancer. 2011 , 3, 88-98	14
648	Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. 2010 , 10, 1-48	23
647	Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference?. 2012 , 4, 226-8	2
646	EURTAC first line therapy for non small cell lung carcinoma in epidermal growth factor receptor mutation positive patients: A choice between two TKIs. 2012 , 4, 221-2	1
645	Personalized therapy for pancreatic cancer: Myth or reality in 2010?. 2010 , 1, 24-33	4
644	Moving forward with circulating tumor cells and lung cancer. 2012 , 4, 440-1	3
643	Re-challenge treatment of small-molecular inhibitors in NSCLC patients beyond progression. 2012 , 4, 647-9	2
642	Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. 2013 , 25, 90-4	12
641	Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. 2012 , 9, 38-43	
640	Principles of biopsy in suspected lung cancer: priority still based on invasion in the era of targeted therapy?. 2013 , 5, E93-7	3
639	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. 2013 , 5, 481-96	13
638	Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. 2013 , 6, 1880-9	22
637	Tyrosine kinase inhibitors re-treatment beyond progression: choice and challenge. 2014 , 6, 595-7	1
636	Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer. 2014 , 7, 4774-81	27
635	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond. 2014 , 11, 173-81	19
634	Validation of the new IASLC/ATS/ERS lung adenocarcinoma classification: a surgeon's perspective. 2014 , 6, S547-51	1
633	Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. 2014 , 6, S568-80	8
632	The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management. 2014 , 6, S589-96	11

631	Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition). 2014 , 6, 1489-98	2
630	Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines. 2014 , 7, 7304-11	7
629	Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies. 2014 , 7, 3833-42	4
628	Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma. 2014 , 26, 705-10	2
627	MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers. 2015 , 5, 1-19	22
626	Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. 2015 , 3, 32	
625	Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?. 2015 , 3, 31	1
624	Neoadjuvant EGFR TKIs: toward personalized management in non-small-cell lung cancer. 2012 , 1, 280-2	1
623	The TORCH trial. 2012 , 1, 283-6	1
622	Expanding options for EGFR targeting in lung cancer. 2012 , 1, 287-8	2
621	Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC. 2012 , 1, 224-6	
620	Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. 2012 , 1, 227-9	
619	Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?. 2012 , 1, 152-4	1
618	TKIs in NSCLC: the down of a new era?. 2012 , 1, 147-8	
617	EGFR-TKIs in EGFR-mutated lung cancer: Setting the new standard for 1(st) line therapy. 2012 , 1, 3-4	1
616	Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy. 2012 , 1, 72-7	3
615	Status quo and prospects of the translational research on lung cancer in China. 2012 , 1, 91-3	
614	Management of elderly patients. 2013 , 2, 200-7	1

613	Keeping our fingers crossed on 2(nd) generation EGFR TKIs: is better good enough?. 2013 , 2, 55-7	
612	Does the order of factors affect the product? Lessons learned from the TORCH trial. 2013 , 2, 50-4	
611	MET inhibition in lung cancer. 2013 , 2, 23-39	11
610	Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. 2013 , 2, 411-4	1
609	Integrin beta-8 (ITGB8) silencing reverses gefitinib resistance of human hepatic cancer HepG2/G cell line. 2015 , 8, 3063-71	15
608	Sarcomatous transformation of EGFR and TP53 mutation-positive metastatic adenocarcinoma of the lungs, masquerading as a primary pleomorphic sarcoma of the proximal femur. 2015 , 8, 3270-8	3
607	Mutation of the epidermal growth factor receptor gene and its impact on the efficacy of gefitinib in advanced non-small cell lung cancer. 2015 , 8, 5397-405	2
606	Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients. 2015 , 27, 294-300	4
605	Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. 2015 , 5, 2229-40	5
604	Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. 2015 , 8, 10330-9	16
603	Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer. 2015 , 8, 11278-86	2
602	Comparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status. 2015 , 8, 13136-45	17
601	Pemetrexed and cyclophosphamide combination therapy for the treatment of non-small cell lung cancer. 2015 , 8, 14693-700	4
600	Afatinib in Non-Small Cell Lung Cancer. 2015 , 6, 448-55	5
599	Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform. 2016 , 13, 68-76	4
598	Role of epidermal growth factor receptor in lung cancer and targeted therapies. 2017 , 7, 187-202	39
597	Methylation of kruppel-like factor 2 (KLF2) associates with its expression and non-small cell lung cancer progression. 2017 , 9, 2024-2037	13
596	Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. 2017 , 18, 107-114	9

595	MafB silencing in macrophages does not influence the initiation and growth of lung cancer induced by urethane. 2017 , 16, 914-920	0
594	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?. 2017 , 34, 405-408	0
593	Molecular Targets in Non-Small Cell Lung Cancer. 2017 , 17, 388-392	14
592	Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. 2016 , 7, 723-735	4
591	Identifying the Causes of Cancer Health Disparities: Biologic and Non Biologic Determinants. 2010 , 8, 101-111	1
590	[Clinical Observation of Gefitinib with Pericardial Perfusion for ?Advanced Non-small Cell Lung Cancer]. 2018 , 21, 37-42	
589	[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment?(2016 version)]. 2016 , 19, 489-94	6
588	[Clinical Experience with First-generation Epidermal Growth Factor Receptor ?Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients ?with Brain Metastasis]. 2017 , 20, 114-123	
587	[Treatment of Patients with ALK-positive Non-small Cell Lung Cancer ?and Brain Metastases]. 2016 , 19, 519-24	1
586	[Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System ?Metastases from Non-small Cell Lung Cancer]. 2016 , 19, 496-500	
585	[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations]. 2016 , 19, 550-8	2
584	[Advances in the Transformation to Small Cell Lung Cancer from Non-small Cell Lung Cancer Following Acquired Drug-resistance to EGFR Tyrosine Kinase Inhibitors]. 2017 , 20, 720-726	1
583	[Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma]. 2017 , 20, 543-548	2
582	[Research Progress of Targeted Therapy for EGFR Gene in Non-small Cell Lung Cancer]. 2017 , 20, 61-65	1
581	[Observation - An Favorable Option Forthoracic Dissemination Patients with Lung Adenocarcinoma or Squamous Carcinoma]. 2018 , 21, 303-309	1
580	[Relationship between EGFR Mutations and Pathological Classification and ?Specimen of Lung Adenocarcinoma]. 2017 , 20, 382-388	1
579	[Molecular Imaging in vivo Detection of EGFR Mutations in Non-small Cell Lung Cancer]. 2017 , 20, 415-420	
578	[EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance]. 2017 , 20, 617-622	3

577	[Primary Application of Radiofrequency Ablation after Locally Progression of EGFR-TKIs in Non-small Cell Lung Cancer]. 2016 , 19, 859-863	1
576	[Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy]. 2011 , 14, 715-8	3
575	[Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy]. 2011 , 14, 699-703	
574	[Modified Restriction Enzyme-based Detection of EGFR Mutations in Lung Cancer]. 2011 , 14, 637-41	
573	[Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer]. 2011 , 14, 261-5	2
572	[The role of adjuvant chemotherapy in operable non-small cell lung cancer]. 2011 , 14, 281-5	
571	[Recent Advances and Prospect of Advanced Non-small Cell Lung Cancer Targeted Therapy: Focus on Small Molecular Tyrosine Kinase Inhibitors]. 2017 , 20, 278-286	1
570	[Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma]. 2011 , 14, 127-31	3
569	[Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report]. 2016 , 19, 52-6	0
568	[Clinical Analysis of Icotinib on Beneficiary of Advanced Non-small Cell Lung Cancer with EGFR Common Mutation]. 2016 , 19, 200-6	3
567	[Nimotuzumab significantly enhances chemosensitivity of PC9 human lung adenocarcinoma cells to paclitaxel in vitro]. 2015 , 18, 98-103	0
566	[Optimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptor]. 2015 , 18, 110-6	
565	[Treatment of patients with ALK gene rearranged non-small cell lung cancer after resistance to crizotinib]. 2015 , 18, 69-74	
564	[EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib]. 2012 , 15, 513-20	1
563	[Advances of molecular subtype and targeted therapy of lung cancer]. 2012 , 15, 545-52	
562	[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975]. 2012 , 15, 127-38	0
561	[Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer]. 2011 , 14, 518-22	4
560	[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy]. 2011 , 14, 529-33	

- 559 [Expressions of c-Cbl, Cbl-b and EGFR and its role of prognosis in NSCLC]. **2011**, 14, 512-7
- 558 [Progress in Tissue Specimens Alternative for the Driver Genes Testing of Non-small Cell Lung Cancer]. **2015**, 18, 387-90
- 557 [Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib]. **2011**, 14, 785-9 0
- 556 [Resistant mechanism and treatment strategy of tyrosine kinase inhibitors]. **2011**, 14, 806-10
- 555 [Evaluation of efficacy and safety of bevacizumab combined with chemotherapy for Chinese patients with advanced non-small cell lung cancer]. **2012**, 15, 6-10 0
- 554 [Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis]. **2012**, 15, 44-8 1
- 553 [Advances of heterogeneity of EGFR in non-small cell lung cancer]. **2011**, 14, 890-3
- 552 [Current status and future direction of multi-targeted drugs in the era of personalized therapy--overview of advances in multi-targeted therapy in non-small cell lung cancer]. **2011**, 14, 874-9
- 551 [Association between the epidermal growth receptor status and the efficacy of first-line chemotherapy in patients with advanced non-small cell lung cancer]. **2015**, 18, 131-7 0
- 550 [Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis]. **2015**, 18, 146-54 0
- 549 [Adverse events of afatinib as first-line treatment for five cases of advanced lung adenocarcinoma and review of literature]. **2014**, 17, 342-6
- 548 [Role of the expression level of Nrf2 in predicting response of EGFR-TKIs in lung adenocarcinoma patients with EGFR gene mutations]. **2014**, 17, 155-62 2
- 547 [Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma]. **2015**, 18, 656-60 3
- 546 [A case report of combined small cell lung cancer with EGFR mutation and treatment experience]. **2014**, 17, 511-4
- 545 [Value of immunohistochemical staining with mutation-specific antibodies in detecting EGFR mutations: a meta-analysis]. **2014**, 17, 451-9
- 544 [Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report]. **2015**, 18, 592-8
- 543 [Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer]. **2015**, 18, 493-9 4
- 542 [Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines]. **2015**, 18, 475-80 5

541	[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)]. 2015 , 18, 397-400	1
540	[EML4-ALK fusion gene in lung cancer and its biological function]. 2012 , 15, 112-6	2
539	[Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer]. 2015 , 18, 240-4	0
538	[TKI Resistance for T790M Mutation]. 2015 , 18, 245-50	1
537	[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China]. 2012 , 15, 332-9	3
536	[Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma]. 2015 , 18, 686-90	1
535	[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1]. 2011 , 14, 385-90	2
534	[Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis]. 2010 , 13, 882-91	10
533	[Detection of epidermal growth factor receptor mutations in non-small cell lung cancer tumor specimens from various ways by denaturing high-performance liquid chromatography]. 2010 , 13, 850-5	1
532	[Research progress of targeted therapy in non-small cell lung cancer brain metastases]. 2014 , 17, 824-8	1
531	[Research progresses of albumin-bound paclitaxel in the treatment of non-small cell lung cancer]. 2010 , 13, 748-52	
530	[Advances on driver oncogenes of lung adenocarcinoma]. 2013 , 16, 91-6	0
529	[Efficacy of gefitinib for young patients with unknown EGFR gene mutation ?in advanced lung adenocarcinoma]. 2014 , 17, 401-5	
528	[Detection of EGFR gene mutations in 100 non-small cell lung cancer clinical samples by a real-time polymerase chain reaction method using amplification refractory mutation system specific primers and Taqman fluorescence probes]. 2013 , 16, 25-32	1
527	[Analysis of prognostic factors in patients with stage IV lung adenocarcinoma after failure of second-line EGFR-TKIs therapy]. 2013 , 16, 38-42	
526	Prospective analysis on survival outcomes of nonsmall cell lung cancer stages over IIIb treated with HangAm-Dan. 2010 , 13, 1009-15	3
525	[Drug induced hepatotoxicity in targeted therapy for lung cancer]. 2014 , 17, 685-8	2
524	[Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer]. 2010 , 13, 247-53	

- 523 [A case report of patient with advanced non-small cell lung cancer by five times EGFR-TKIs therapy]. **2013**, 16, 330-2
- 522 [Detection and evaluation of EGFR mutation status in serum of patients with advanced non-small cell lung cancer treated with EGFR-TKIs]. **2013**, 16, 303-7 1
- 521 [Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas]. **2013**, 16, 177-83 3
- 520 [Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride]. **2013**, 16, 240-5 4
- 519 [Application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer]. **2010**, 13, 48-53 3
- 518 Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung. **2017**, 8, 267-272
- 517 [Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer]. **2013**, 16, 547-52 1
- 516 [Treatment choice for advanced non-small cell lung cancer patients who had gradual progression after EGFR-TKIs: 32 cases report]. **2013**, 16, 524-8
- 515 [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma]. **2013**, 16, 529-34
- 514 [Blood-based Tumor Markers in Lung Cancer]. **2015**, 18, 770-80
- 513 [Graphic Evolution Witness the Development of Lung Cancer Translational Research]. **2016**, 19, 403-8
- 512 [Efficacy of S-1 in Advanced Non-small Cell Lung Cancer Patients Treated with More Than Two Lines of Chemotherapy]. **2018**, 21, 437-444
- 511 [Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome]. **2013**, 16, C9-20
- 510 [Personalized targeted therapy for lung cancer]. **2013**, 16, C21-34
- 509 [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. **2010**, 13, 238-41
- 508 Development of metastatic brain disease involves progression through lung metastases in mutated non-small cell lung cancer. **2017**, 3, 3
- 507 [Disparities of EGFR mutations between Biopsy and Rebiopsy in Non-small Cell Lung Cancer Patients]. **2018**, 21, 821-827
- 506 [Molecular Mechanism of Different Signaling Pathways in Regulating PD-L1 Expression in EGFR Mutated Lung Adenocarcinoma]. **2018**, 21, 875-879 2

- 505 Effect of EGFR gene polymorphism on efficacy of chemotherapy combined with targeted therapy for non-small cell lung cancer in Chinese patients. **2019**, 9, 619-627 6
- 504 [Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them]. **2019**, 22, 299-305
- 503 [Matrine inhibits proliferation and promotes autophagy and apoptosis in non-small cell lung cancer cells by deactivating PI3K/AKT/mTOR pathway]. **2019**, 39, 760-765 3
- 502 The characterization of lung microbiome in lung cancer patients with different clinicopathology. **2019**, 9, 2047-2063 17
- 501 Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSF1A and GADD45 promoter. **2019**, 12, 4002-4010 5
- 500 Comparison of clinicopathologic characteristics between patients with EGFR exon 19 deletion and EGFR L858R mutation in lung cancer. **2018**, 11, 4644-4649
- 499 Accuracy and clinical influence of plasma EGFR mutation detection in management of advanced lung adenocarcinoma. **2017**, 10, 9559-9566
- 498 Abnormal E-cadherin expression and reduced tumor-infiltrating T cells are related to poor progression in non-small cell lung cancer. **2017**, 10, 11572-11579 1
- 497 [Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer]. **2020**, 23, 55-59
- 496 Cell-Free Circulating Tumour DNA Blood Testing to Detect T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment. **2020**, 20, 1-176 3
- 495 Mental disorder or conscious disturbance in epidermal growth factor receptor-tyrosine kinase inhibitor treatment of advanced lung adenocarcinoma. **2020**, 19, 230-238 2
- 494 [Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI]. **2020**, 23, 381-387 1
- 493 [Treatment for Brain Metastases from EGFR Mutations NSCLC Patients: How Should We Choose in Clinical Practice?]. **2020**, 23, 631-637
- 492 Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells. **2020**, 20, 206 2
- 491 Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists. **2020**, 9, 2194-2198 1
- 490 Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status. **2020**, 12, 5505-5516
- 489 [Pathological and Molecular Features of Lung Micropapillary Adenocarcinoma]. **2020**, 23, 1007-1013
- 488 [Results of EGFR Mutations Detected in Pleural Effusion and Its Clinical Significance in 132 Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Study in A Single Center]. **2020**, 23, 1059-1065 1

487	Predicting mutation status in lung adenocarcinoma: development and validation of a computed tomography-based radiomics signature. 2021 , 11, 546-560	6
486	[Semiquantitative parameters of F-FDG PET/CT, gene mutation states of epidermal growth factor receptor and anaplastic lymphoma kinase in prognosis evaluation of patients with lung adenocarcinoma]. 2020 , 53, 246-254	
485	[Review on the Combination Strategy of Anti-angiogenic Agents and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer]. 2021 , 24, 357-364	
484	[Comprehensive Treatment of An Advanced Lung Cancer Patient with EGFR Driver Gene Positive]. 2021 , 24, 447-452	
483	[Progress in Single-cell RNA Sequencing of Lung Adenocarcinoma]. 2021 , 24, 434-440	
482	Survival and prognosis analyses of concurrent PIK3CA mutations in EGFR mutant non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. 2021 , 11, 3189-3200	0
481	Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant Brain Metastasis and Spinal Cord Metastasis Models. 2021 , 12, 750031	2
480	Recent advances in lung cancer genomics: Application in targeted therapy. 2021 , 108, 201-275	0
479	The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. 2021 , 169, 103561	3
478	Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. 2021 , 1877, 188645	4
477	The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. 2021 ,	26
476	DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. 2021 , 13,	1
475	Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. 2021 , 163, 14-18	0
474	Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. 2021 ,	7
473	I/CuCl-Copromoted Formal [4 + 1 + 1] Cyclization of Methyl Ketones, 2-Aminobenzonitriles, and Ammonium Acetate: Direct Access to 2-Acyl-4-aminoquinazolines. 2021 , 86, 16916-16925	1
472	The need for speed in advanced non-small cell lung cancer: A population kinetics assessment. 2021 ,	5
471	Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review. 2021 , 22,	
470	Identification of lncRNA-miRNA-mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor. 2021 , 12, 758591	2

- 469 Remodeling of dermal adipose tissue alleviates cutaneous toxicity induced by anti-EGFR therapy.
- 468 KRAS mutation: from undruggable to druggable in cancer. **2021**, 6, 386 22
- 467 Feasibility and safety of shortened hypofractionated high dose palliative lung radiotherapy â retrospective planning study.
- 466 Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids. **2021**, 12, 2375-2387 0
- 465 Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis. **2021**, 23, 408-417
- 464 Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world. **2021**, 11, 86 6
- 463 Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.. **2021**, 0
- 462 Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review. **2021**, 14, 5363-5372 0
- 461 VLX1570 regulates the proliferation and apoptosis of human lung cancer cells through modulating ER stress and the AKT pathway. **2021**, 2
- 460 Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs. **2021**, 1
- 459 Non-proportional hazards â An evaluation of the MaxCombo Test in cancer clinical trials. 1-12 0
- 458 Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology. **2021**, 13, 1
- 457 Nicht-kleinzelliges Lungenkarzinom: Wandel und Mglichkeiten der molekularen Diagnostik.
- 456 Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT).. **2021**, 13, 17588359211059874 1
- 455 Role of surgical treatment in patients with EGFR mutation-positive locally advanced and disseminated non-small-cell lung cancer. **2021**, 10, 56
- 454 Encyclopedia of Gerontology and Population Aging. **2021**, 4895-4908
- 453 Immunotherapy related pericardial effusion on chest CT. **2021**, 82, 204-209 0
- 452 Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.. **2021**, 162, 99-106 4

451	DESCRIPTIVE ANALYSIS OF LUNG CANCER LATERALITY AND EGFR MUTATION IN QUITOECUADOR. 2019 , 142-143	
450	Effects of hyperinsulinemia on acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor via the PI3K/AKT pathway in non-small cell lung cancer cells in vitro. 2020 , 20, 1-1	2
449	Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status. 2020 , 12, 5505-5516	
448	Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists. 2020 , 9, 2194-2198	1
447	Root Extract of Scutellaria Baicalensis Increases Gefitinib Sensitivity in H1975 Human Non-small Cell Lung Cancer Cells. 2021 , 35, 117-123	
446	Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.. 2021 ,	3
445	Pretreatment neutrophil-to-lymphocyte ratio and cigarette smoking as prognostic factors in patients with advanced NSCLC treated with osimertinib.. 2022 ,	1
444	Accounting for EGFR mutations in epidemiological analyses of non-small cell lung cancers: Examples based on the International Lung Cancer Consortium data.. 2022 ,	
443	Identification of Targetable Liabilities in the Dynamic Metabolic Profile of -Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance.. 2022 , 10,	0
442	Local ablative radiotherapy on oligo-progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer patients: A longer cohort.. 2022 ,	0
441	The co-mutation of and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients.. 2022 , 14, 185-193	1
440	Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer.. 2022 , 12,	0
439	A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy.. 2022 , 10, 101	
438	Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome.. 2022 , 31, 100524	0
437	Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).. 2022 ,	1
436	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.. 2022 , 27,	5
435	Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion.. 2022 ,	1
434	First-Line Tyrosine Kinase Inhibitors Combined With Local Consolidative Radiation Therapy for Elderly Patients With Oligometastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations.. 2022 , 12, 766066	0

433	Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC.. 2022 ,	4
432	Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up.. 2022 ,	1
431	Predicting Anticancer Drug Resistance Mediated by Mutations.. 2022 , 15,	0
430	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.. 2022 , JCO2101626	8
429	Biomarkers in Pulmonary Carcinomas. 2022 , 99-128	0
428	A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.. 2022 , 17, 1-13	3
427	Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study.. 2022 , 31, 100526	
426	Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis.. 2021 , 11, 766148	1
425	Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma.. 2022 , 14,	0
424	Experiencia inicial de detección de mutaciones en biopsia tumoral y líquida de pacientes con adenocarcinoma pulmonar. 2022 , 33, 68-74	
423	Prevalence of targeted therapy-related genetic variations in NSCLC and their relationship with clinicopathological characteristics.. 2022 , 17, e0262822	
422	Alkaloids and Colon Cancer: Molecular Mechanisms and Therapeutic Implications for Cell Cycle Arrest.. 2022 , 27,	1
421	Liquid biopsy: the value of different bodily fluids.. 2022 , 16, 127-145	1
420	Effects of Ethnicity on Outcomes of Patients With Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection.. 2022 , 3, 100259	0
419	Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.. 2022 , 120, 105605	1
418	Study on First-Generation TKIs in the Treatment of Patients with Unresectable EGFR-Mutation-Positive Non-Small-Cell Lung Cancer. 2022 , 12, 761-770	
417	A Simple and Highly Sensitive Naked-Eye Analysis of EGFR 19del via CRISPR/Cas12a Triggered No-Nonspecific Nucleic Acid Amplification.. 2022 ,	1
416	Optimal Initial Time Point of Local Radiotherapy for Unresectable Lung Adenocarcinoma: A Retrospective Analysis on Overall Arrangement of Local Radiotherapy in Advanced Lung Adenocarcinoma.. 2022 , 12, 793190	1

415	Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa - KINDLE Study.. 2022 ,	0
414	Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected -mutated non-small-cell lung cancer: a meta-analysis.. 2022 ,	0
413	Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases.. 2022 , 1	1
412	Liquid Biopsy, Diagnostic Imaging, and Future Synergies.. 2022 , 19, 336-343	1
411	Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells.. 2022 , 38, 110343	1
410	The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.. 2022 , 12, 843299	0
409	Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.. 2022 , 17, e0263629	0
408	Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/ECatenin activity and cancer stemness.. 2022 , 531, 83-83	2
407	CCN2 Binds to Tubular Epithelial Cells in the Kidney.. 2022 , 12,	0
406	Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.. 2022 , 12, 2167	1
405	Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes.. 2022 ,	0
404	Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer.. 2021 , 10,	0
403	"How Long Have I Got?" in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question.. 2021 , 11, 761042	4
402	Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report.. 2022 , 16, 30	0
401	Non-Small Cell Lung Cancer in Older Adults with Frailty. 2022 , 319-339	
400	Neurological complications of lung cancer. 2022 , 243-276	
399	Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.. 2022 , 31, 100534	1
398	Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.. 2022 , 14, 17588359221079125	0

397	A two-phase comprehensive NSCLC prognostic study identifies lncRNAs with significant main effect and interaction.. 2022 , 297, 591	0
396	The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.. 2022 , 42, 221	
395	MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer.. 2021 ,	5
394	Concurrent lung adenocarcinoma and bladder diffuse large B-cell lymphoma: a case report and literature review.. 2022 , 50, 3000605221081672	1
393	Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers.. 2022 , 9, 847835	3
392	Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.. 2022 , 21, 61	0
391	Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR-TKIs in a real-world clinical setting.. 2022 , 16, 88	0
390	Severe stomatitis caused by osimertinib combined with gefitinib: A case report.. 2022 , 10, e05396	1
389	LUNG CANCER. 2022 , 89-91	
388	Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).. 2022 , 29, 1107-1116	
387	The Role of Mutations in -Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy.. 2022 , 14,	0
386	Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma.. 2022 , 14, 1293-1302	
385	Comparison of sampling methods for next generation sequencing for patients with lung cancer.. 2022 ,	1
384	A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.. 2022 ,	2
383	Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.. 2022 ,	4
382	Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).. 2022 , 22, 294	
381	Association between clinical outcomes and local treatment in stage IV non-small cell lung cancer patients with single extrathoracic metastasis.. 2022 ,	1
380	Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERR β -expression.. 2022 , 21, 77	3

379	Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy.. 2022 , 14,	0
378	Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (-TKI) in -Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients.. 2022 , 14, 863-873	0
377	Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?. 2022 , 22, 323	1
376	Direct Targeting Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.. 2022 , 14,	0
375	mA demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small-cell lung cancer.. 2022 ,	0
374	Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.. 2022 ,	
373	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.. 2022 , 12, 869672	3
372	A concise review on tyrosine kinase targeted cancer therapy. 2022 , 17,	
371	The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis.. 2022 , 12, 4398	0
370	Group sequential design for randomized trials using "first hitting time" model.. 2022 ,	0
369	ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression?. 2022 , 13, 13-21	0
368	An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer.. 2022 , 1-6	1
367	The Magic of ADAURA?. 2022 , 17, 348-350	0
366	Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).. 2022 ,	3
365	Hepatic Rupture as the Initial Presentation of an -Mutated Lung Adenocarcinoma: A Case Report.. 2022 , 12, 837630	
364	MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.. 2022 , 20, 27	0
363	Aumolertinib: A Review in Non-Small Cell Lung Cancer.. 2022 , 82, 577	1
362	Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer.. 2022 , 13, 1667	5

- 361 F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs.. **2022**, 14, ○
- 360 Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA-IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study.. **2022**, 9, 816018
- 359 Comparative survival analysis of platinum-based adjuvant chemotherapy for early-stage squamous cell carcinoma and adenocarcinoma of the lung.. **2022**, 1
- 358 Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis.. **2022**, 3, 100322 ○
- 357 Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC.. **2022**, 1 ○
- 356 Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations.. **2022**, 7, 100398 ○
- 355 Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma.. **2022**, 22, 470
- 354 Novel targeted therapies for advanced non-small lung cancer.. **2022**, ○
- 353 Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.. **2022**, 12, 853501
- 352 Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: A review of phase II and III trials.. **2022**, ○
- 351 The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan.. **2022**, ○
- 350 The RNA editing enzyme ADAR modulated by the rs1127317 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.. **2022**, 296, 120408 ○
- 349 Histologic transformation of epidermal growth factor receptor-mutated lung cancer.. **2022**, 166, 41-50 1
- 348 Dynamic EGFR interactomes reveal differential association of signaling modules with wildtype and Exon19-del EGFR in NSCLC cell lines.. **2022**, 104555
- 347 Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report.. **2021**, 12, 809467 ○
- 346 Long Term Survival in Patients with Metastatic Adenocarcinoma of the Lung in the Era of Targeted Agents. **2021**, 1, 41-54
- 345 Cancer-immunotherapy biomarkers in the tumor microenvironment. **2021**, 133, 151-157
- 344 Targeted Therapy Followed by Salvage Surgery and Adjuvant Therapy: A Promising Therapy for Lung Cancer With Malignant Pleural Effusion From a Case Report.. **2021**, 8, 659983 ○

343	Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.. 2021 , 28, 5179-5191	1
342	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.. 2021 , 2, 692-729	2
341	HPLC-DAD Based Polyphenolic Profiling and Evaluation of Pharmacological Attributes of Wall.. 2021 , 27,	1
340	The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management.. 2021 , 21, 675	1
339	Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment.. 2021 , 10,	0
338	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.. 2021 , 5, 102	2
337	Basic Understandings of EGFR-mutated Lung Cancer and Its Clinical Applications. 2021 , 61, 911-918	
336	Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models. 2021 , 12, 750031	5
335	Neoadjuvant gefitinib therapy: a potential standard therapy for non-small cell lung cancer.. 2022 , 14, 799-801	
334	Exceptional response to afatinib in a patient with persistent G719A -mutant NSCLC.. 2022 , 11, LMT54	0
333	Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.. 2022 , 82, 649	2
332	EGFR signaling pathway as therapeutic target in human cancers.. 2022 ,	1
331	A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and F-FDG Metabolic Activity in Non-Small Cell Lung Cancer.. 2022 , 12, 780186	1
330	Improving ovarian cancer treatment decision using a novel risk predictive tool.. 2022 , 14,	0
329	Structural features and anticancer mechanisms of pectic polysaccharides: A review.. 2022 , 209, 825-839	1
328	Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.. 2022 , 237, 114381	0
327	Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. 499-517	
326	Image_1.TIF. 2020 ,	

325 Table_1.XLSX. 2020,

324 Table_2.XLSX. 2020,

323 Table_1.DOCX. 2020,

322 Data_Sheet_1.docx. 2020,

321 Table_1.DOCX. 2020,

320 Data_Sheet_1.pdf. 2020,

319 Table_1.docx. 2020,

318 Table_2.docx. 2020,

317 Table_1.docx. 2020,

316 Image_1.JPEG. 2019,

315 Image_2.jpg. 2019,

314 Image_3.jpeg. 2019,

313 Image_4.jpeg. 2019,

312 Data_Sheet_1.docx. 2019,

311 Data_Sheet_2.docx. 2019,

310 Data_Sheet_1.XLSX. 2020,

309 Table_1.docx. 2020,

308 Table_1.docx. 2020,

307 Table_2.docx. **2020**,

306 Table_1.DOC. **2020**,

305 Table_2.DOC. **2020**,

304 Table_3.XLSX. **2020**,

303 DataSheet_1.docx. **2021**,

302 Image_1.tiff. **2021**,

301 Image_2.tiff. **2021**,

300 Image_3.tiff. **2021**,

299 DataSheet_1.docx. **2019**,

298 DataSheet_2.docx. **2019**,

297 DataSheet_3.doc. **2019**,

296 DataSheet_4.docx. **2019**,

295 Image_1.tif. **2019**,

294 Table_1.DOCX. **2018**,

293 The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.. **2022**, 1

292 Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction.. **2022**, 12, 6693

291 Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non-small-cell lung cancer.. **2022**,

290 [Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer ?with Epidermal Growth Factor Receptor Gene Mutation].. **2022**, 25, 183-192

289	[Relationship between EGFR, ALK Gene Mutation and Imaging ?and Pathological Features in Invasive Lung Adenocarcinoma].. 2022 , 25, 147-155	
288	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as âROS1âs it appears?. 2017 , 34, 405	2
287	Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.. 2022 , 12, 7002	0
286	Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.. 2022 ,	0
285	Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.. 2022 , 14,	1
284	Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer.. 2022 , 8, eabn1229	1
283	Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.. 2022 , 20, 497-530	24
282	Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors.. 2022 , 8, eabm6638	1
281	Association between epidermal growth factor receptor gene mutation status and short-term efficacy of first-line platinum-containing chemotherapy in advanced non-small cell lung cancer. 2022 , 17,	
280	Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.. 2022 , 22, 514	1
279	A comparison of methods for enriching network meta-analyses in the absence of individual patient data.. 2022 ,	
278	Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.. 2022 ,	
277	Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.. 2022 , 7, 157	0
276	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.. 2022 ,	2
275	Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis.. 2022 , 17, e0268288	1
274	Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.. 2022 , 22, 179	1
273	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.. 2022 , 14,	0
272	A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01).. 2022 ,	

271	Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule. 2022 , 13,	0
270	Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer.. 2022 ,	0
269	B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors.. 2022 , 20, 159	1
268	Machine learning-based algorithm demonstrates differences in del19 and L858R EGFR subgroups in non-small cell lung cancer: a single center experience.. 2022 , 14, 2677-2684	
267	First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.	1
266	Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. 2022 , 14, 2613	0
265	Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. 2022 , 12,	0
264	The Immun-Enhancing and Synergistic Antitumor Efficacy of Lienal Polypeptide Combined with EGFR-TKIs for Advanced NSCLC.	
263	Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC. 2022 , 14, 2744	1
262	Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients.	0
261	Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib. 2022 , 22,	
260	Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario. 2022 , 10,	
259	Multiple Primary Lung Cancers With ALK Rearrangement: A Case Report and Literature Review. 12,	
258	AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer. 2022 , 12,	0
257	Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer. 2022 , 14, 2661	1
256	When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan. 2022 , 22,	0
255	Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review. 2022 , 13,	1
254	Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer.	

- 253 Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. **2022**, 1
- 252 Beyond standard data collection – the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry). **2022**, 22, 0
- 251 30- und 90-Tage-Letalität bei Patienten mit Lungenkarzinom im Stadium IV in Abhängigkeit der Primärtherapie. **2022**, 43, 321-330
- 250 Advances in the Biology and Molecular Study of Brain Metastasis from Non-Small Cell Lung Cancer. **2022**, 12, 5561-5568
- 249 Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC. **2022**, 16, 117955492211032 0
- 248 Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations. **2022**, 27, 3844 0
- 247 Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis. 12, 0
- 246 MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. 1
- 245 The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors. **2022**, 14, 3011
- 244 PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. **2022**, 12, 1
- 243 Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients.
- 242 Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia. Volume 14, 1995-2005
- 241 Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: Analysis of vital registration data from the WHO Mortality Database between 2000 and 2017. **2022**, 0
- 240 Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-small Cell Lung Cancer. 13, 0
- 239 New PET Tracers: Current Knowledge and Perspectives in Lung Cancer. **2022**, 0
- 238 Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?. **2022**, 23, 6936 2
- 237 Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first-line setting. 0
- 236 Loop-Mediated Isothermal Amplification as Point-of-Care Testing for EGFR-Mutated Lung Adenocarcinoma. **2022**, 13, 897

- 235 EGFR, NF- κ B and noncoding RNAs in precision medicine. **2022**,
- 234 Circulating cancer biomarkers: current status and future prospects. **2022**, 409-443
- 233 Synthetic Lethality and Lung Cancer. **2022**, 51-62
- 232 Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer. **2022**, 12,
- 231 Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study. 0
- 230 Cost-effectiveness of osimertinib versus placebo in resected EGFR -mutated non-small cell lung cancer in China.
- 229 Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World. **2022**, 12, 0
- 228 Clinical Experience on Use of Oral EGFR-TKIs as First-line Treatment of Advanced NSCLC from a Tertiary Care Centre in North India and Implications of Skin Rash. **2022**, 56, 149-152
- 227 A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif[®] in healthy Chinese subjects.
- 226 State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. **2022**, 23, 7037 0
- 225 Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms. **2022**, 63, 700-708 0
- 224 Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. **2022**, 0
- 223 Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis. **2022**, 14, 3362
- 222 Treating advanced lung cancer in older veterans with comorbid conditions and frailty. **2022**,
- 221 Two phenotypes that predict prognosis in lung adenocarcinoma. **2022**, 60, 2200569
- 220 Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer. **2022**, 12, 0
- 219 Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA. 1
- 218 Clinico-pathological Profile of Lung Cancer Patients in a Tertiary Care Hospital, India: A Prospective, Cross-sectional Study. **2022**, 64, 79-85

- 217 Sandwich strategy to intensify EGFR blockade by concurrent tyrosine kinase inhibitor and monoclonal antibody treatment in highly selected patients. 12, 0
- 216 Neuronal survival factor VGF promotes chemoresistance and predicts poor prognosis in lung cancers with neuroendocrine feature.
- 215 Real-world KINDLE-Latin America subset data on treatment patterns and clinical outcomes in patients with stage III non-small-cell lung cancer.
- 214 Evaluation of the implementation of Value-Based Healthcare with a weekly digital follow-up of lung cancer patients in clinical practice.
- 213 Novel anilino-pyrimidine derivatives as potential EGFR T790M/C797S inhibitors: Design, synthesis, biological activity study. **2022**, 70, 116907 0
- 212 Highly sensitive detection of EGFR L858R mutation at the mRNA level. **2022**, 654, 114799
- 211 Lung Cancer. **2023**, 57-78
- 210 Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. **2015**, 44, 449-462 2
- 209 Targeted Therapy in Early Stage Non-small Cell Lung Cancer. 1
- 208 Two distinct primary EGFR-mutated lung adenocarcinoma within the same patient: A case report.
- 207 Host-related factors as targetable drivers of immunotherapy response in non-small cell lung cancer patients. 13, 0
- 206 Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation. 12, 0
- 205 Metastatic lung tumors from colorectal cancer with EGFR mutations that responded to osimertinib. **2022**, 0
- 204 MiR-21/Sonic Hedgehog (SHH)/PI3K/AKT pathway is associated with NSCLC of primary EGFR-TKI resistance. **2022**, 1-12
- 203 The therapy of osimertinib for EGFR mutation non-small cell lung cancer. 6, 219-229
- 202 Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor. 0
- 201 Overexpression of 14-3-3 primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC. **2022**, 14, 5838-5854 1
- 200 The presence of EGFR T790M in TKI-naïve lung cancer samples of patients who developed a T790M-positive relapse on first or second generation TKI is rare. **2022**, 14, 3511

199	Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials.	2
198	Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. 13,	
197	CCT6A and CHCHD2 Are Coamplified with EGFR and Associated with the Unfavorable Clinical Outcomes of Lung Adenocarcinoma. 2022 , 2022, 1-16	
196	Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. 2022 , 23, 8541	0
195	Use of thyroid transcription factor 1 and napsin A to predict local failure and survival after Gamma Knife radiosurgery in patients with brain metastases from lung adenocarcinoma. 2022 , 1-11	
194	Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804). 2022 , 39,	0
193	Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC Patients. 2022 ,	
192	The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: A real-world study.	
191	The effect of intrathoracic lesion location on initial tyrosine kinase inhibitor response in advanced oncogene-addicted non-small cell lung cancer: A comparison between RECIST 1.1 and a novel method of response assessment (MAX).. 2022 ,	
190	PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. 12,	1
189	The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2022 , 29, 6137-6153	2
188	Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study.	
187	Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK / RAS pathway in ground-glass opacity pulmonary nodules.	0
186	KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. 2022 , 23, 9391	0
185	The nomogram for the prediction of overall survival in patients with metastatic lung adenocarcinoma undergoing primary site surgery: A retrospective population-based study. 12,	1
184	Exploratory Evaluation of EGFR-Targeted Anti-Tumor Drugs for Lung Cancer Based on Lung-on-a-Chip. 2022 , 12, 618	1
183	Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities. Publish Ahead of Print,	0
182	Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. 13,	1

181	L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment. 2022 , 13,	0
180	The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study. 2022 , 12,	
179	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. 12,	0
178	EGFR-mutant NSCLC: monitoring the molecular evolution of tumors in 2022.	0
177	The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion. 2022 , 12,	2
176	The Ethanolic Extract of Trichosanthes Kirilowii Root Exerts anti-Cancer Effects in Human Non-Small Cell Lung Cancer Cells Resistant to EGFR TKI. 1-12	
175	Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study. 2022 ,	0
174	Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma. 12,	
173	The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010. 2022 , 22,	1
172	Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field. 12,	
171	Drug resistance in NSCLC is associated with tumor micro-environment. 2022 , 22, 100680	0
170	PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug. 2022 , 237, 154065	0
169	Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs. 2022 , 128, 106057	0
168	Translational Research in Lung Cancer. 2022 ,	0
167	Targeted Therapies in Non-small Cell Lung Cancer. 2022 ,	1
166	Genomic Alterations in Lung Cancer. 2022 ,	0
165	Substanzen gegen molekulare Zielstrukturen. 2022 , 1-14	0
164	Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification. 2022 , 21, 153303382211284	0

163	Regulation of Signaling from the Epidermal Growth Factor Family.	0
162	A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11). 2022 ,	0
161	Regulation of Signaling from the Epidermal Growth Factor Family. 2022 , 126, 7475-7485	0
160	Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma (Review). 2022 , 24,	2
159	Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations. 2022 , 22,	0
158	The Impact of Comorbidities, Neutrophil-to-lymphocyte Ratio, and Adverse Events on Quality of Life in Lung Cancer Patients Receiving EGFR-TKI Therapy.	0
157	A Machine Learning-Based Predictive Model of Epidermal Growth Factor Mutations in Lung Adenocarcinomas. 2022 , 14, 4664	0
156	Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. 12,	0
155	Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan. 1078155222 ⁹ 1220	0
154	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy.	0
153	Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer. 2022 , 22,	0
152	Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature.	0
151	Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.	0
150	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. 13,	0
149	Stratifin as a novel diagnostic biomarker in serum for diffuse alveolar damage. 2022 , 13,	0
148	Generation of genetically engineered mice for lung cancer with mutant EGFR. 2022 , 632, 85-91	0
147	Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. 2022 , 251-267	0
146	Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. 2022 ,	0

145	Promotion of multidisciplinary collaboration in cancer chemotherapyâbasic knowledge of medicines for clinical nurses. 2022 , 157, 416-420	0
144	How Genome-Wide Analysis Contributes to Personalized Treatment in Cancer, Including Gynecologic Cancer?. 2022 , 115-132	0
143	Birden Fazla SâMutasyonlu KâHâre Olmayan Akciâr Kanserli Hastalarda Optimum Yaklaâmân Hangi Tedavi Seâmelidir? Bir Vaka Raporu ve Literatârâncelemesi.	0
142	Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Nonâsmall-Cell Lung Cancer. 2022 ,	1
141	UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN). 2022 ,	1
140	New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer. 2022 , 23, 1626-1644	1
139	Algorithme thârapeutique des cancers bronchiques non ^petites cellules tendus avec mutation de lâEGFR. 2022 , 14, 2S189-2S208	0
138	Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. 2022 , 119,	0
137	Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing. 2022 , 12, 1684	0
136	Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.	0
135	Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced EGFR-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-Analysis. 2022 , 14, 4894	0
134	Advanced Lung Cancer PatientsâUse of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada. 2022 , 29, 8043-8073	0
133	Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients âan overview. 12,	0
132	Cancer of the Lung. 1-29	0
131	Global research trends on precision oncology: A systematic review, bibliometrics, and visualized study. 2022 , 101, e31380	0
130	Analyse de la prise en charge des cancers bronchiques avec mutation du gâne de lâEGFR. 2022 ,	0
129	Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects by Epidermal growth factor inhibitor treatments.	0
128	Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.	0

127	EGFR testing in paraffin-embedded cell block cytology material is reliable with increased detection for effusion fluid. 2022,	0
126	Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches. 2022, 19, 14324	0
125	Amoud Class for Hazard-Based and Odds-Based Regression Models: Application to Oncology Studies. 2022, 11, 606	0
124	Durable clinical response to immunotherapy in EGFR-mutated lung adenocarcinoma with squamous cell carcinoma transformation and high expression of PD-L1 after resistance development: A case report. 2022, 8, 100199	0
123	Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade. 2017, 46, 333-338	3
122	Real-world outcomes of anti-EGFR therapy in advanced non-small cell lung cancer EGFR mutated in Peru.	0
121	The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.	0
120	Segmentectomy for clinically early-stage primary squamous cell carcinoma of the lung.	0
119	EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors. 13,	0
118	Toll-like receptor 2 orchestrates a tumor suppressor response in non-small cell lung cancer. 2022, 41, 111596	1
117	Clinicopathologic outcomes of preoperative targeted therapy in patients with clinical stage I-III non-small cell lung cancer. 2022,	0
116	Changes in survival of patients with non-small cell lung cancer in Japan: an interrupted time series study.	0
115	Usage of Epidermal Growth Factor Mutation Testing and impact on treatment patterns in Non-Small Cell Lung Cancer: An International Observational Study. 2022,	0
114	Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. 13,	0
113	Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. 2022, 7, 100605	0
112	Topical Zhiyang Pingfu Liquid for Moderate to Severe Skin Rash Associated With EGFRIs: A double-blinded randomized controlled trial. 2022, 21, 153473542211404	0
111	Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study. 2022, 21, 153303382211382	0
110	A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival. 2023, 175, 68-78	0

- 109 Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions. **2023**, 206, 107093 ○
- 108 Single-cell transcriptional profiling uncovers the association between EOMES+CD8+ T cells and acquired EGFR-TKI resistance. **2023**, 66, 100910 ○
- 107 Heterogeneity and Clinical Effect of Epidermal Growth Factor Receptor in Primary Lung and Brain Metastases of Nonsmall Cell Lung Cancer. **2023**, 283, 674-682 ○
- 106 Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. **2022**, 14, 175883592211440 ○
- 105 ASTRIS, estudio de mundo real con osimertinib en pacientes EGFR mutados, progresados con T790M. **2018**, 23, ○
- 104 MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going. **2022**, 14, 5731 ○
- 103 Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit. 12, ○
- 102 The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis. **2022**, 24, 340-344 ○
- 101 A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation. ○
- 100 Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan. ○
- 99 Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. **2022**, 24, 269-304 ○
- 98 CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer. ○
- 97 PROTAC therapy as a new targeted therapy for lung cancer. **2022**, ○
- 96 Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study. **2022**, ○
- 95 Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). **2022**, 22, ○
- 94 Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma. **2022**, 1-12 ○
- 93 Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights. **2022**, 27, 8901 ○
- 92 EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. **2022**, 41, 111827 ○

91	Clinical case of long-term disease control in a patient with <i>EGFR</i>-positive non-small cell lung cancer. 2022 , 154-159	o
90	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. 2022 , 3,	o
89	TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. 2022 , 14, 6127	o
88	Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs. 2022 , 101, e32169	o
87	Stereotactic ablative radiotherapy for acquired resistance to EGFR therapy in metastatic non-small cell lung cancer. 12,	o
86	Tumour Genetics and Genomics to Personalise Cancer Treatment. 2011 , 40, 362-368	o
85	Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.	o
84	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.	1
83	EGFR-Directed Therapy in Lung Cancer. 2023 ,	o
82	Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies. 2023 , 108347	o
81	Negative impact of the microvascular area to tumor area ratio on the response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer with EGFR mutation.	o
80	Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery. Volume 18, 263-276	o
79	Updates in pathology and molecular diagnostics to inform the evolving landscape of thoracic surgery and oncology. 2023 , 127, 244-257	o
78	SurvSHAP(t): Time-dependent explanations of machine learning survival models. 2023 , 262, 110234	o
77	Covariate-adjusted response-adaptive designs for censored survival responses. 2023 , 225, 219-242	o
76	Importancia del test de mutaci3n del receptor del factor de crecimiento epid3mico en c3ncer de pulm3n de c3lulas no pequeas. 2015 , 20,	o
75	The surgical resection of the primary tumor increases survival in patients with EGFR-mutant advanced non-small cell lung cancer: a tertiary center cohort study. 2022 , 12,	o
74	Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes. 2023 , 15, 187	o

- 73 Autocrine EGF and TGF- β promote primary and acquired resistance to ALK / c-Met kinase inhibitors in non-small-cell lung cancer. **2023**, 11, ○
- 72 Negative impact of the microvascular area to tumor area ratio on the response to EGFR-TKI in NSCLC with EGFR mutation. ○
- 71 FACILITATE: A real-world, multicenter, prospective study investigating the utility of a rapid, fully automated real-time PCR assay versus local reference methods for detecting epidermal growth factor receptor variants in NSCLC. 29, ○
- 70 Gender is a non-negligible risk factor affecting the overall survival time of NSCLC patients: a nationwide population-based study. ○
- 69 Current clinically validated applications of liquid biopsy. **2023**, 63-81 ○
- 68 Synthesis, Molecular Dynamics Simulation, and In-vitro Antitumor Activity of Quinazoline-2,4,6-triamine Derivatives as Novel EGFR Tyrosine Kinase Inhibitors. **2023**, 21, ○
- 67 Historical development of EGFR-targeted therapy. **2023**, 1-11 ○
- 66 Systemic treatment and radiotherapy for patients with non-small cell lung cancer (NSCLC) and HIV infection – systematic review. **2023**, ○
- 65 High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma. **2023**, ○
- 64 Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer. **2023**, 2023, 1-21 ○
- 63 Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations. **2023**, 15, 175883592211461 ○
- 62 Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. **2023**, ○
- 61 Treatment of Isolated Intracranial Progression of Lung Cancer During Treatment with Systemic Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs). 19-28 ○
- 60 Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients. **2023**, 669, 115115 ○
- 59 Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer. ○
- 58 A multiparametric fluorescent visualization approach for detecting drug resistance in living cancer cells. **2023**, 259, 124564 ○
- 57 Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. **2023**, 15, 629 ○
- 56 Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-small Cell Lung Cancer. **2023**, 13, 210 ○

- 55 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 ○
- 54 Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. **2023**, 153, 40039 ○
- 53 Liquid Biopsy for Oral Cancer Diagnosis: Recent Advances and Challenges. **2023**, 13, 303 ○
- 52 Dopamine agonists and risk of lung cancer in patients with restless legs syndrome. ○
- 51 CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. **2023**, 41, 340-355.e6 ○
- 50 Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials. **2023**, 21, ○
- 49 Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review. **2023**, 102, e32697 ○
- 48 Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced myocardial damage: a case report and literature review. Publish Ahead of Print, ○
- 47 Machine Learning in Lung Cancer Radiomics. ○
- 46 Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer. **2023**, 46, 161-166 ○
- 45 Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC. **2023**, 24, 4126 ○
- 44 CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations. 13, ○
- 43 Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations. ○
- 42 Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial. **2023**, 8, ○
- 41 Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III-IV lung adenocarcinoma. **2023**, 22, 5-14 ○
- 40 Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer. **2023**, 21, ○
- 39 Real-World Data on EGFR and ALK Testing and TKI Usage in NorwayâA Nation-Wide Population Study. **2023**, 15, 1505 ○
- 38 Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer. **2023**, 178, 229-236 ○

- 37 Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide. ○
- 36 The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer. **2023**, 24, 4827 ○
- 35 Evolution of cancer genomics and its clinical implications. **2019**, 9, 173-178 ○
- 34 Nomogram prediction for the risk of venous thromboembolism in patients with lung cancer. **2023**, 23, ○
- 33 Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. **2023**, 184, 103954 ○
- 32 Clinical effectiveness reporting of novel cancer drugs in the context of non-proportional hazards: a review of nice single technology appraisals. **2023**, 39, ○
- 31 Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC). 13, ○
- 30 A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. **2023**, 8, 101183 ○
- 29 Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR . ○
- 28 Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs. **2023**, 24, 5821 ○
- 27 CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma. **2023**, 23, ○
- 26 Molecular Pathology of Lung Cancer. ○
- 25 EBUS-TBNA of Right Lower Paratracheal Lymph Node (Station 4R). **2012**, 192-206 ○
- 24 Rigid Bronchoscopy with Y Stent Insertion at Left Secondary Carina. **2012**, 291-298 ○
- 23 Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib. **2023**, 15, 2019 ○
- 22 Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. **2023**, 14, ○
- 21 Ultra-rapid Idylla®EGFR mutation screening followed by next-generation sequencing: An integrated solution to molecular diagnosis of non-small cell lung cancer. 13, ○
- 20 New targeted therapies for non-small cell lung cancer. **2023**, 66, 180-190 ○

- 19 Feasibility and safety of shortened hypofractionated high-dose palliative lung radiotherapy â retrospective planning study. **2023**, 108, 102559
- 18 Another prognostic marker for hepatocellular carcinoma. **2023**, 17, 279-280
- 17 Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017âPresent). **2023**, 16, 534
- 16 Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. **2023**,
- 15 Inhibition of the mitochondria-shaping protein Opa1 restores sensitivity to Gefitinib in a lung adenocarcinoma-resistant cell line. **2023**, 14,
- 14 Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.
- 13 Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice. 14,
- 12 Concomitant TP53 mutation in early-stage resected EGFR-mutated non-small cell lung cancer: a narrative approach in a genetically admixed Brazilian cohort. 56,
- 11 The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis. **2023**, 2023, 1-8
- 10 Structure Activity relationship and Computational Study Mediated Insights on the EGFR Inhibition of Epigallocatechin gallate Against Lung Cancer.
- 9 Insights into the metastatic cascade through research autopsies. **2023**,
- 8 Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer. 13,
- 7 Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments. **2023**, 259, 124553
- 6 Emerging evidence and treatment paradigm of non-small cell lung cancer. **2023**, 16,
- 5 Personalized treatment for patients with lung cancer.
- 4 Targeted therapy for lung cancer: Beyond EGFR and ALK.
- 3 An association of epidermal growth factor receptor mutation subtypes with prognostic prediction and site-specific recurrence in advanced stage lung cancer patients.
- 2 Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country. **2023**, 30, 107327482311752

- 1 FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma. **2023**, 15, 3644-3677

o